Cancer Cells Display Profound Intra- and Interline Vari
Exposure to Antimitotic Drugs

Cancer Cell

14, 111-122

DOI: 10.1016/j.ccr.2008.07.002

Citation Report

#	Article	IF	Citations
1	Overproduction of cerebrospinal fluid in communicating hydrocephalus. Neurology, 1973, 23, 1-1.	1.5	34
2	Network pharmacology: the next paradigm in drug discovery. Nature Chemical Biology, 2008, 4, 682-690.	3.9	3,165
3	Beyond Genetics: Surprising Determinants of Cell Fate in Antitumor Drugs. Cancer Cell, 2008, 14, 103-105.	7.7	12
4	The Mad2 partial unfolding model: regulating mitosis through Mad2 conformational switching. Journal of Cell Biology, 2008, 183, 761-768.	2.3	51
5	Characterizing heterogeneous cellular responses to perturbations. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 19306-19311.	3.3	161
6	Multipolar Spindle Pole Coalescence Is a Major Source of Kinetochore Mis-Attachment and Chromosome Mis-Segregation in Cancer Cells. PLoS ONE, 2009, 4, e6564.	1.1	374
7	An Intermittent Live Cell Imaging Screen for siRNA Enhancers and Suppressors of a Kinesin-5 Inhibitor. PLoS ONE, 2009, 4, e7339.	1.1	20
8	The future of targeted therapy approaches in melanoma. Expert Opinion on Drug Discovery, 2009, 4, 445-456.	2.5	1
9	Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 19108-19113.	3.3	274
10	Quantitative Assessment of the Complex Dynamics of G1, S, and G2-M Checkpoint Activities. Cancer Research, 2009, 69, 5234-5240.	0.4	25
11	BRD8 is a potential chemosensitizing target for spindle poisons in colorectal cancer therapy. International Journal of Oncology, 2009, 35, 1101-9.	1.4	30
12	p53-dependent apoptosis in response to spindle damage is linked to loss of Bub1. Cancer Biology and Therapy, 2009, 8, 645-647.	1.5	6
13	Radiosensitization by Chir-124, a selective Chk1 inhibitor: Effects of p53 and cell cycle checkpoints. Cell Cycle, 2009, 8, 1196-1205.	1.3	54
14	An ATM and ATR dependent pathway targeting centrosome dependent spindle assembly. Cell Cycle, 2009, 8, 1997-2001.	1.3	12
16	Role of prolonged mitotic checkpoint activation in the formation and treatment of cancer. Future Oncology, 2009, 5, 1363-1370.	1.1	23
17	Pharmacologic Abrogation of the Mitotic Spindle Checkpoint by an Indolocarbazole Discovered by Cellular Screening Efficiently Kills Cancer Cells. Cancer Research, 2009, 69, 3874-3883.	0.4	32
18	Length of mitotic arrest induced by microtubule-stabilizing drugs determines cell death after mitotic exit. Molecular Cancer Therapeutics, 2009, 8, 1646-1654.	1.9	73
19	Belmontâ„¢ Hyperthermia Pump in the conduct of intra-operative heated chemotherapy. Perfusion (United Kingdom), 2009, 24, 115-118.	0.5	2

#	Article	IF	Citations
20	Oncogenic Adenomatous Polyposis Coli Mutants Impair the Mitotic Checkpoint through Direct Interaction with Mad2. Molecular Biology of the Cell, 2009, 20, 2381-2388.	0.9	13
21	Cells satisfy the mitotic checkpoint in Taxol, and do so faster in concentrations that stabilize syntelic attachments. Journal of Cell Biology, 2009, 186, 675-684.	2.3	81
22	Chromosomal instability determines taxane response. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 8671-8676.	3.3	244
23	Distinct Concentration-Dependent Effects of the Polo-like Kinase 1â€“Specific Inhibitor GSK461364A, Including Differential Effect on Apoptosis. Cancer Research, 2009, 69, 6969-6977.	0.4	102
24	Cell-cycle control in the face of damage â€“ a matter of life or death. Trends in Cell Biology, 2009, 19, 89-98.	3.6	124
25	A Novel Protein Phosphatase 1-Dependent Spindle Checkpoint Silencing Mechanism. Current Biology, 2009, 19, 1176-1181.	1.8	150
26	Cancer: CINful Centrosomes. Current Biology, 2009, 19, R642-R645.	1.8	16
27	Evidence that Mitotic Exit Is a Better Cancer Therapeutic Target Than Spindle Assembly. Cancer Cell, 2009, 16, 347-358.	7.7	273
28	No Way Out for Tumor Cells. Cancer Cell, 2009, 16, 274-275.	7.7	14
29	High content image cytometry in the context of subnuclear organization. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2010, 77A, 64-75.	1.1	42
30	9â€bromonoscapineâ€induced mitotic arrest of cigarette smoke condensateâ€transformed breast epithelial cells. Journal of Cellular Biochemistry, 2009, 106, 1146-1156.	1.2	16
31	Mitotic driversâ€”inhibitors of the Aurora B Kinase. Cancer and Metastasis Reviews, 2009, 28, 185-195.	2.7	66
32	Kinesin motor proteins as targets for cancer therapy. Cancer and Metastasis Reviews, 2009, 28, 197-208.	2.7	171
33	Responding to chromosomal breakage during M-phase: insights from a cell-free system. Cell Division, 2009, 4, 15.	1.1	5
34	The nature of cell-cycle checkpoints: facts and fallacies. Journal of Biology, 2009, 8, 88.	2.7	43
35	Chromosome segregation machinery and cancer. Cancer Science, 2009, 100, 1158-1165.	1.7	35
36	A mechanism linking extra centrosomes to chromosomal instability. Nature, 2009, 460, 278-282.	13.7	1,254
37	UBE2S elongates ubiquitin chains on APC/C substrates to promote mitotic exit. Nature Cell Biology, 2009, 11, 1363-1369.	4.6	217

#	Article	IF	Citations
38	Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis. Nature Reviews Molecular Cell Biology, 2009, 10, 478-487.	16.1	745
39	Paclitaxel promotes a caspase 8-mediated apoptosis through death effector domain association with microtubules. Oncogene, 2009, 28, 3551-3562.	2.6	50
40	RanBP1 downregulation sensitizes cancer cells to taxol in a caspase-3-dependent manner. Oncogene, 2009, 28, 1748-1758.	2.6	34
41	Apoptosis and autophagy: Regulation of caspaseâ€9 by phosphorylation. FEBS Journal, 2009, 276, 6063-6073.	2.2	176
42	Non-genetic cell-to-cell variability and the consequences for pharmacology. Current Opinion in Chemical Biology, 2009, 13, 556-561.	2.8	200
43	A Class of 2,4-Bisanilinopyrimidine Aurora A Inhibitors with Unusually High Selectivity against Aurora B. Journal of Medicinal Chemistry, 2009, 52, 3300-3307.	2.9	74
44	A little CIN may cost a lot: revisiting aneuploidy and cancer. Current Opinion in Genetics and Development, 2009, 19, 74-81.	1.5	56
45	EM011 activates a survivin-dependent apoptotic program in human non-small cell lung cancer cells. Molecular Cancer, 2009, 8, 93.	7.9	31
46	How do anti-mitotic drugs kill cancer cells?. Journal of Cell Science, 2009, 122, 2579-2585.	1.2	321
47	Working Hypothesis: Elimination of Cancer Stem Cells in Solid Tumors by Immuno-Gene Therapy Using Cancer Vaccines and Created-Inhibitory RNA. Current Cancer Therapy Reviews, 2009, 5, 217-226.	0.2	0
48	Effects of chemical manipulation of mitotic arrest and slippage on cancer cell survival and proliferation. Cell Cycle, 2009, 8, 3029-3042.	1.3	35
49	Dividing the goods: co-ordination of chromosome biorientation and mitotic checkpoint signalling by mitotic kinases. Biochemical Society Transactions, 2009, 37, 971-975.	1.6	7
50	Tumor suppressor interactions with microtubules: keeping cell polarity and cell division on track. DMM Disease Models and Mechanisms, 2010, 3, 304-315.	1.2	24
51	Adapt or die: how eukaryotic cells respond to prolonged activation of the spindle assembly checkpoint. Biochemical Society Transactions, 2010, 38, 1645-1649.	1.6	18
52	The â€˜anaphase problemâ€™: how to disable the mitotic checkpoint when sisters split. Biochemical Society Transactions, 2010, 38, 1660-1666.	1.6	14
53	Cell Cycle-Associated Kinases as Targets for Therapy in Lung Cancer. Journal of Thoracic Oncology, 2010, 5, S461-S462.	0.5	10
54	Cyclin A and Nek2A: APC/Câ€“Cdc20 substrates invisible to the mitotic spindle checkpoint. Biochemical Society Transactions, 2010, 38, 72-77.	1.6	28
55	Mechanisms of Chromosomal Instability. Current Biology, 2010, 20, R285-R295.	1.8	480

#	Article	IF	Citations
56	Mutations in the human kinesin Eg5 that confer resistance to monastrol and S-trityl-l-cysteine in tumor derived cell lines. Biochemical Pharmacology, 2010, 79, 864-872.	2.0	39
57	Fine tuning chemotherapy to match BRCA1 status. Biochemical Pharmacology, 2010, 80, 647-653.	2.0	14
58	Pharmacologic Inhibition of the Anaphase-Promoting Complex Induces A Spindle Checkpoint-Dependent Mitotic Arrest in the Absence of Spindle Damage. Cancer Cell, 2010, 18, 382-395.	7.7	285
59	Targeting Mitotic Exit Leads to Tumor Regression InÂVivo: Modulation by Cdk1, Mastl, and the PP2A/B55Î±,Î´ Phosphatase. Cancer Cell, 2010, 18, 641-654.	7.7	188
60	Nocodazole induces mitotic cell death with apoptoticâ€like features in Saccharomyces cerevisiae. FEBS Letters, 2010, 584, 2387-2392.	1.3	28
61	The DNA damage response to non-replicating adeno-associated virus: Centriole overduplication and mitotic catastrophe independent of the spindle checkpoint. Virology, 2010, 400, 271-286.	1.1	10
62	Upregulated Op18/stathmin activity causes chromosomal instability through a mechanism that evades the spindle assembly checkpoint. Experimental Cell Research, 2010, 316, 2017-2026.	1.2	10
63	Mitotic drug targets. Journal of Cellular Biochemistry, 2010, 111, 258-265.	1.2	34
64	Temporal proteome profiling of taxolâ€induced mitotic arrest and apoptosis. Electrophoresis, 2010, 31, 1873-1885.	1.3	14
65	Cell cycle and cell death in disease: past, present and future. Journal of Internal Medicine, 2010, 268, 395-409.	2.7	54
66	The BH3-only protein Bad confers breast cancer taxane sensitivity through a nonapoptotic mechanism. Oncogene, 2010, 29, 5381-5391.	2.6	24
67	The centrosomal protein TACC3 controls paclitaxel sensitivity by modulating a premature senescence program. Oncogene, 2010, 29, 6184-6192.	2.6	47
68	Defining the role of APC in the mitotic spindle checkpoint in vivo: APC-deficient cells are resistant to Taxol. Oncogene, 2010, 29, 6418-6427.	2.6	29
69	Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes. Oncogene, 2010, 29, 6085-6098.	2.6	123
70	Phosphorylation of Mcl-1 by CDK1â€“cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest. EMBO Journal, 2010, 29, 2407-2420.	3.5	297
71	CLASP1, astrin and Kif2b form a molecular switch that regulates kinetochore-microtubule dynamics to promote mitotic progression and fidelity. EMBO Journal, 2010, 29, 3531-3543.	3.5	123
72	Tumor-initiating activity and tumor morphology of HNSCC is modulated by interactions between clonal variants within the tumor. Laboratory Investigation, 2010, 90, 1594-1603.	1.7	26
73	An essential role for p73 in regulating mitotic cell death. Cell Death and Differentiation, 2010, 17, 787-800.	5.0	35

#	Article	IF	Citations
74	Mitotic chromosomal instability and cancer: mouse modelling of the human disease. Nature Reviews Cancer, 2010, 10, 102-115.	12.8	377
75	Microtubules and resistance to tubulin-binding agents. Nature Reviews Cancer, 2010, 10, 194-204.	12.8	930
76	Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nature Reviews Cancer, 2010, 10, 825-841.	12.8	548
77	Tetraploid cancer cell precursors. Nature Reviews Molecular Cell Biology, 2010, 11, 539-539.	16.1	7
78	Stochastic Competition between Mechanistically Independent Slippage and Death Pathways Determines Cell Fate during Mitotic Arrest. PLoS ONE, 2010, 5, e15724.	1.1	56
79	Preclinical Evaluation of AMG 900, a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines. Cancer Research, 2010, 70, 9846-9854.	0.4	109
80	Targeting the Mitotic Checkpoint for Cancer Therapy with NMS-P715, an Inhibitor of MPS1 Kinase. Cancer Research, 2010, 70, 10255-10264.	0.4	152
81	Antitumor activity of an allosteric inhibitor of centromere-associated protein-E. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 5839-5844.	3.3	197
82	BRAF Inactivation Drives Aneuploidy by Deregulating CRAF. Cancer Research, 2010, 70, 8475-8486.	0.4	40
83	Docetaxel-Resistant Prostate Cancer Cells Remain Sensitive toS-Trityl-<scp>l</scp>-Cysteineâ€“Mediated Eg5 Inhibition. Molecular Cancer Therapeutics, 2010, 9, 1730-1739.	1.9	30
84	The RSC chromatin-remodeling complex influences mitotic exit and adaptation to the spindle assembly checkpoint by controlling the Cdc14 phosphatase. Journal of Cell Biology, 2010, 191, 981-997.	2.3	44
85	Mcl-1 Stability Determines Mitotic Cell Fate of Human Multiple Myeloma Tumor Cells Treated with the Kinesin Spindle Protein Inhibitor ARRY-520. Molecular Cancer Therapeutics, 2010, 9, 2046-2056.	1.9	65
86	APC16 is a conserved subunit of the anaphase-promoting complex/cyclosome. Journal of Cell Science, 2010, 123, 1623-1633.	1.2	27
87	Nek4 Status Differentially Alters Sensitivity to Distinct Microtubule Poisons. Cancer Research, 2010, 70, 1033-1041.	0.4	33
88	Activity of the Kinesin Spindle Protein Inhibitor Ispinesib (SB-715992) in Models of Breast Cancer. Clinical Cancer Research, 2010, 16, 566-576.	3.2	75
89	Mps1 directs the assembly of Cdc20 inhibitory complexes during interphase and mitosis to control M phase timing and spindle checkpoint signaling. Journal of Cell Biology, 2010, 190, 89-100.	2.3	164
90	A conserved G₁regulatory circuit promotes asynchronous behavior of nuclei sharing a common cytoplasm. Cell Cycle, 2010, 9, 3795-3803.	1.3	26
91	Cell death when the SAC is out of commission. Cell Cycle, 2010, 9, 2049-2050.	1.3	7

#	Article	IF	Citations
92	Destruction's our delight: Controlling apoptosis during mitotic arrest. Cell Cycle, 2010, 9, 4035-4036.	1.3	5
93	Substrate degradation by the anaphase promoting complex occurs during mitotic slippage. Cell Cycle, 2010, 9, 1792-1801.	1.3	35
94	Protein phosphatase 2A contributes to separase regulation and the co-ordination of anaphase. Bioscience Horizons, 2010, 3, 66-76.	0.6	1
95	Centriole duplication. Cell Cycle, 2010, 9, 2803-2808.	1.3	43
96	Celastrol causes apoptosis and cell cycle arrest in rat glioma cells. Neurological Research, 2010, 32, 94-100.	0.6	55
97	Measurement of Constitutive MAPK and PI3K/AKT Signaling Activity in Human Cancer Cell Lines. Methods in Enzymology, 2010, 484, 549-567.	0.4	14
98	Genes that Modulate the Sensitivity for Anti-Microtubule Drug-Mediated Chemotherapy. Current Cancer Drug Targets, 2010, 10, 623-633.	0.8	13
99	An automated fluorescence videomicroscopy assay for the detection of mitotic catastrophe. Cell Death and Disease, 2010, 1, e25-e25.	2.7	37
100	A Chemosensitization Screen Identifies TP53RK, a Kinase that Restrains Apoptosis after Mitotic Stress. Cancer Research, 2010, 70, 6325-6335.	0.4	27
101	Patterns of basal signaling heterogeneity can distinguish cellular populations with different drug sensitivities. Molecular Systems Biology, 2010, 6, 369.	3.2	116
102	Checkpoint kinase 1 modulates sensitivity to cisplatin after spindle checkpoint activation in SW620 cells. International Journal of Biochemistry and Cell Biology, 2010, 42, 318-328.	1.2	5
103	A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations. Cell, 2010, 141, 69-80.	13.5	2,162
104	Cellular Heterogeneity: Do Differences Make a Difference?. Cell, 2010, 141, 559-563.	13.5	968
106	Microfluidics-integrated time-lapse imaging for analysis of cellular dynamics. Integrative Biology (United Kingdom), 2010, 2, 278.	0.6	26
107	Convergent Synthesis and Biological Evaluation of 2-Amino-4-(3â€²,4â€²,5â€²-trimethoxyphenyl)-5-aryl Thiazoles as Microtubule Targeting Agents. Journal of Medicinal Chemistry, 2011, 54, 5144-5153.	2.9	79
108	APC15 drives the turnover of MCC-CDC20 to make the spindle assembly checkpoint responsive to kinetochore attachment. Nature Cell Biology, 2011, 13, 1234-1243.	4.6	139
109	Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer. Cancer Research, 2011, 71, 6019-6029.	0.4	400
111	Measuring and Modeling Apoptosis in Single Cells. Cell, 2011, 144, 926-939.	13.5	354

#	Article	IF	Citations
112	The STARD9/Kif16a Kinesin Associates with Mitotic Microtubules and Regulates Spindle Pole Assembly. Cell, 2011, 147, 1309-1323.	13.5	67
113	Rapid induction of apoptosis during Kinesin-5 inhibitor-induced mitotic arrest in HL60 cells. Cancer Letters, 2011, 310, 15-24.	3.2	13
114	Homeostatic Control of Mitotic Arrest. Molecular Cell, 2011, 44, 710-720.	4.5	94
115	Tales from an academic RNAi screening facility; FAQs. Briefings in Functional Genomics, 2011, 10, 227-237.	1.3	5
116	Design and Synthesis of 2-Heterocyclyl-3-arylthio-1‹i›H‹/i›-indoles as Potent Tubulin Polymerization and Cell Growth Inhibitors with Improved Metabolic Stability. Journal of Medicinal Chemistry, 2011, 54, 8394-8406.	2.9	70
117	Spindle Poisons and Cell Fate: A Tale of Two Pathways. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2011, 11, 141-150.	3.4	108
118	Cell Death Signaling and Anticancer Therapy. Frontiers in Oncology, 2011, 1, 5.	1.3	46
119	A Time-Series Method for Automated Measurement of Changes in Mitotic and Interphase Duration from Time-Lapse Movies. PLoS ONE, 2011, 6, e25511.	1.1	17
120	Monitoring the fidelity of mitotic chromosome segregation by the spindle assembly checkpoint. Cell Proliferation, 2011, 44, 391-400.	2.4	62
121	How APC/Câ€“Cdc20 changes its substrate specificity inÂmitosis. Nature Cell Biology, 2011, 13, 223-233.	4.6	100
122	Mitotic catastrophe: a mechanism for avoiding genomic instability. Nature Reviews Molecular Cell Biology, 2011, 12, 385-392.	16.1	682
123	Phosphatases: providing safe passage through mitotic exit. Nature Reviews Molecular Cell Biology, 2011, 12, 469-482.	16.1	275
124	IC261 induces cell cycle arrest and apoptosis of human cancer cells via CK1Î´/É› and Wnt/Î²-catenin independent inhibition of mitotic spindle formation. Oncogene, 2011, 30, 2558-2569.	2.6	101
125	Mitosis as an anti-cancer target. Oncogene, 2011, 30, 2799-2809.	2.6	92
126	PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cells. British Journal of Cancer, 2011, 104, 281-289.	2.9	27
127	Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature, 2011, 471, 110-114.	13.7	682
128	A novel microtubule-modulating noscapinoid triggers apoptosis by inducing spindle multipolarity via centrosome amplification and declustering. Cell Death and Differentiation, 2011, 18, 632-644.	5.0	61
129	Caspase-3-mediated degradation of condensin Cap-H regulates mitotic cell death. Cell Death and Differentiation, 2011, 18, 996-1004.	5.0	26

#	Article	IF	Citations
130	Merotelic kinetochore attachment: causes and effects. Trends in Cell Biology, 2011, 21, 374-381.	3.6	215
131	Measuring enzyme activity in single cells. Trends in Biotechnology, 2011, 29, 222-230.	4.9	84
132	Cell-to-Cell Variability in PI3K Protein Level Regulates PI3K-AKT Pathway Activity in Cell Populations. Current Biology, 2011, 21, 173-183.	1.8	91
133	Synergistic antimicrotubule therapy for prostate cancer. Biochemical Pharmacology, 2011, 81, 478-487.	2.0	18
134	Analysis of Mitosis and Antimitotic Drug Responses in Tumors by In Vivo Microscopy and Single-Cell Pharmacodynamics. Cancer Research, 2011, 71, 4608-4616.	0.4	146
135	Mitosis in vertebrates: the G2/M and M/A transitions and their associated checkpoints. Chromosome Research, 2011, 19, 291-306.	1.0	94
136	In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines. Cancer Chemotherapy and Pharmacology, 2011, 67, 637-646.	1.1	63
137	Targeting the Mitotic Checkpoint to Kill Tumor Cells. Hormones and Cancer, 2011, 2, 113-116.	4.9	31
138	Cdc20 control of cell fate during prolonged mitotic arrest. BioEssays, 2011, 33, 903-909.	1.2	15
139	Navitoclax (ABT-263) Accelerates Apoptosis during Drug-Induced Mitotic Arrest by Antagonizing Bcl-xL. Cancer Research, 2011, 71, 4518-4526.	0.4	101
140	Cyclin B1 interacts with the BH3-only protein Bim and mediates its phosphorylation by Cdk1 during mitosis. Cell Cycle, 2011, 10, 3886-3896.	1.3	23
141	A new level of spindle assembly checkpoint inactivation that functions without mitotic spindles. Cell Cycle, 2011, 10, 3805-3806.	1.3	8
142	Targeting βIII-Tubulin in Glioblastoma Multiforme: From Cell Biology and Histopathology to Cancer Therapeutics. Anti-Cancer Agents in Medicinal Chemistry, 2011, 11, 719-728.	0.9	25
143	Targeting mitotic exit for cancer treatment. Expert Opinion on Therapeutic Targets, 2011, 15, 785-788.	1.5	6
144	Aurora B: A New Prognostic Marker and Therapeutic Target in Cancer. Current Medicinal Chemistry, 2011, 18, 482-496.	1.2	74
145	Caspase-3â€“Dependent Mitotic Checkpoint Inactivation by the Small-Molecule Inducers of Mitotic Slippage SU6656 and Geraldol. Molecular Cancer Therapeutics, 2011, 10, 839-849.	1.9	13
146	Caspase activity is not required for the mitotic checkpoint or mitotic slippage in human cells. Molecular Biology of the Cell, 2011, 22, 2470-2479.	0.9	11
147	Navitoclax Enhances the Efficacy of Taxanes in Nonâ€“Small Cell Lung Cancer Models. Clinical Cancer Research, 2011, 17, 1394-1404.	3.2	80

#	Article	IF	Citations
148	Inhibition of Dynamin by Dynole 34-2 Induces Cell Death following Cytokinesis Failure in Cancer Cells. Molecular Cancer Therapeutics, 2011, 10, 1553-1562.	1.9	51
149	Molecular and cellular pathways associated with chromosome 1p deletions during colon carcinogenesis. Clinical and Experimental Gastroenterology, 2011, 4, 75.	1.0	12
150	Microtubule disruption targets HIF-1Î± mRNA to cytoplasmic P-bodies for translational repression. Journal of Cell Biology, 2011, 192, 83-99.	2.3	87
151	Targeting aneuploid cancer cells. Expert Opinion on Therapeutic Targets, 2011, 15, 595-608.	1.5	15
152	Modulating Microtubule Stability Enhances the Cytotoxic Response of Cancer Cells to Paclitaxel. Cancer Research, 2011, 71, 5806-5817.	0.4	49
153	Bub1 and BubR1: at the Interface between Chromosome Attachment and the Spindle Checkpoint. Molecular and Cellular Biology, 2011, 31, 3085-3093.	1.1	104
154	Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays. Clinical Cancer Research, 2011, 17, 7614-7624.	3.2	254
155	Cooperative Phosphorylation of FADD by Aur-A and Plk1 in Response to Taxol Triggers Both Apoptotic and Necrotic Cell Death. Cancer Research, 2011, 71, 7207-7215.	0.4	38
156	Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells. Nature Communications, 2011, 2, 395.	5.8	76
157	Anaphase Catastrophe Is a Target for Cancer Therapy. Clinical Cancer Research, 2011, 17, 1218-1222.	3.2	54
158	Regulated inactivation of the spindle assembly checkpoint without functional mitotic spindles. EMBO Journal, 2011, 30, 2648-2661.	3.5	16
159	Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase. Cancer Research, 2011, 71, 675-685.	0.4	43
160	Cdk1 promotes kinetochore bi-orientation and regulates Cdc20 expression during recovery from spindle checkpoint arrest. EMBO Journal, 2012, 31, 403-416.	3.5	14
161	The proliferation rate paradox in antimitotic chemotherapy. Molecular Biology of the Cell, 2012, 23, 1-6.	0.9	297
162	Up-regulation of the mitotic checkpoint component Mad1 causes chromosomal instability and resistance to microtubule poisons. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2205-14.	3.3	75
163	Monitoring APC/C activity in the presence of chromosomal misalignment in unperturbed cell populations. Cell Cycle, 2012, 11, 310-321.	1.3	16
164	Cell death detection by quantitative three-dimensional single-cell tomography. Biomedical Optics Express, 2012, 3, 2111.	1.5	15
165	Linking abnormal mitosis to the acquisition of DNA damage. Journal of Cell Biology, 2012, 199, 871-881.	2.3	178

#	Article	IF	Citations
166	Cell cycle regulation by the NEK family of protein kinases. Journal of Cell Science, 2012, 125, 4423-33.	1.2	289
167	Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells. British Journal of Cancer, 2012, 107, 1692-1701.	2.9	32
168	Cyclin G1 regulates the outcome of taxane-induced mitotic checkpoint arrest. Oncogene, 2012, 31, 2450-2460.	2.6	34
169	Disruption of Tacc3 function leads to in vivo tumor regression. Oncogene, 2012, 31, 135-148.	2.6	35
170	Depletion of p31comet Protein Promotes Sensitivity to Antimitotic Drugs. Journal of Biological Chemistry, 2012, 287, 21561-21569.	1.6	26
171	Microtubules Regulate Hypoxia-inducible Factor-1Î± Protein Trafficking and Activity. Journal of Biological Chemistry, 2012, 287, 11859-11869.	1.6	57
172	The microtubule poison vinorelbine kills cells independently of mitotic arrest and targets cells lacking the APC tumour suppressor more effectively. Journal of Cell Science, 2012, 125, 887-895.	1.2	25
173	Frequent Increased Gene Copy Number and High Protein Expression of tRNA (Cytosine-5-)-Methyltransferase (NSUN2) in Human Cancers. DNA and Cell Biology, 2012, 31, 660-671.	0.9	95
174	Prolonged mitotic arrest triggers partial activation of apoptosis, resulting in DNA damage and p53 induction. Molecular Biology of the Cell, 2012, 23, 567-576.	0.9	203
175	Androgen Receptor on the Move: Boarding the Microtubule Expressway to the Nucleus. Cancer Research, 2012, 72, 4611-4615.	0.4	127
176	Navitoclax (ABT-263) Reduces Bcl-xLâ€“Mediated Chemoresistance in Ovarian Cancer Models. Molecular Cancer Therapeutics, 2012, 11, 1026-1035.	1.9	94
177	The Mad1â€“Mad2 balancing act â€“ a damaged spindle checkpoint in chromosome instability and cancer. Journal of Cell Science, 2012, 125, 4197-206.	1.2	52
178	Cyclin-dependent Kinase-1 (Cdk1)/Cyclin B1 Dictates Cell Fate after Mitotic Arrest via Phosphoregulation of Antiapoptotic Bcl-2 Proteins. Journal of Biological Chemistry, 2012, 287, 39193-39204.	1.6	53
179	Multiple Cancer Testis Antigens Function To Support Tumor Cell Mitotic Fidelity. Molecular and Cellular Biology, 2012, 32, 4131-4140.	1.1	69
180	New 2-Aryl-1,4-naphthoquinone-1-oxime Methyl Ether Compound Induces Microtubule Depolymerization and Subsequent Apoptosis. Journal of Pharmacological Sciences, 2012, 118, 467-478.	1.1	7
181	GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo. Clinical Cancer Research, 2012, 18, 3901-3911.	3.2	75
182	Centrosomes, chromosome instability (CIN) and aneuploidy. Current Opinion in Cell Biology, 2012, 24, 809-815.	2.6	103
183	Up-regulation of Pro-apoptotic Protein Bim and Down-regulation of Anti-apoptotic Protein Mcl-1 Cooperatively Mediate Enhanced Tumor Cell Death Induced by the Combination of ERK Kinase (MEK) Inhibitor and Microtubule Inhibitor. Journal of Biological Chemistry, 2012, 287, 10289-10300.	1.6	22

#	Article	IF	Citations
184	APC/C-Cdh1-dependent anaphase and telophase progression during mitotic slippage. Cell Division, 2012, 7, 4.	1.1	18
185	Mitosis-targeted anti-cancer therapies: where they stand. Cell Death and Disease, 2012, 3, e411-e411.	2.7	240
186	Inhibitors Targeting Mitosis: Tales of How Great Drugs against a Promising Target Were Brought Down by a Flawed Rationale. Clinical Cancer Research, 2012, 18, 51-63.	3.2	192
187	Centrosome amplification in tumorigenesis. Cancer Letters, 2012, 322, 8-17.	3.2	66
188	Chromoanagenesis and cancer: mechanisms and consequences of localized, complex chromosomal rearrangements. Nature Medicine, 2012, 18, 1630-1638.	15.2	231
189	Time-Lapse Imaging of Neuroblastoma Cells to Determine Cell Fate upon Gene Knockdown. PLoS ONE, 2012, 7, e50988.	1.1	17
190	Towards experimental manipulation of stochasticity in gene expression. Progress in Biophysics and Molecular Biology, 2012, 110, 44-53.	1.4	16
191	Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death and Differentiation, 2012, 19, 107-120.	5.0	2,144
192	Inhibitors of Phosphatidylinositol 3â€²-Kinases Promote Mitotic Cell Death in HeLa Cells. PLoS ONE, 2012, 7, e35665.	1.1	67
193	Cohesion Fatigue Explains Why Pharmacological Inhibition of the APC/C Induces a Spindle Checkpoint-Dependent Mitotic Arrest. PLoS ONE, 2012, 7, e49041.	1.1	40
194	Promoter methylation of RASSF1A modulates the effect of the microtubule-targeting agent docetaxel in breast cancer. International Journal of Oncology, 2012, 41, 611-620.	1.4	16
195	Knockdown expression of Apc11 leads to cell-cycle distribution reduction in G2/M phase. Genetics and Molecular Research, 2012, 11, 2814-2822.	0.3	6
196	CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploidâ€specific cancer cell death through autophagy induction. Journal of Pathology, 2012, 226, 482-494.	2.1	48
197	Low MAD2 expression levels associate with reduced progressionâ€free survival in patients with highâ€grade serous epithelial ovarian cancer. Journal of Pathology, 2012, 226, 746-755.	2.1	64
198	Losing balance: the origin and impact of aneuploidy in cancer. EMBO Reports, 2012, 13, 501-514.	2.0	239
199	A telomere-dependent DNA damage checkpoint induced by prolonged mitotic arrest. Nature Structural and Molecular Biology, 2012, 19, 387-394.	3.6	147
200	Kinesins and cancer. Nature Reviews Cancer, 2012, 12, 527-539.	12.8	412
201	Killing cells by targeting mitosis. Cell Death and Differentiation, 2012, 19, 369-377.	5.0	198

#	Article	IF	Citations
202	Occurrence of Aurora A positive multipolar mitoses in distinct molecular classes of colorectal carcinomas and effect of Aurora A inhibition. Molecular Carcinogenesis, 2012, 51, 696-710.	1.3	11
203	Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. EMBO Molecular Medicine, 2012, 4, 675-684.	3.3	223
204	DYZâ€2â€90, a Novel Neoâ€tanshinlactone Ringâ€Opened Compound, Induces ERKâ€Mediated Mitotic Arrest and Subsequent Apoptosis by Activating JNK in Human Colorectal Cancer Cells. ChemBioChem, 2012, 13, 1663-1672.	1.3	7
205	The microtubule cytoskeleton is required for a G2 cell cycle delay in cancer cells lacking stathmin and p53. Cytoskeleton, 2012, 69, 278-289.	1.0	20
206	Paclitaxel sensitivity of breast cancer cells requires efficient mitotic arrest and disruption of Bcl-xL/Bak interaction. Breast Cancer Research and Treatment, 2012, 133, 917-928.	1.1	44
207	Causes and consequences of aneuploidy in cancer. Nature Reviews Genetics, 2012, 13, 189-203.	7.7	700
208	Down-regulation of Fer induces ROS levels accompanied by ATM and p53 activation in colon carcinoma cells. Cellular Signalling, 2012, 24, 1369-1374.	1.7	14
209	Cell fate after mitotic arrest in different tumor cells is determined by the balance between slippage and apoptotic threshold. Toxicology and Applied Pharmacology, 2012, 258, 384-393.	1.3	24
210	Novel Anti-cancer Compounds for Developing Combinatorial Therapies to Target Anoikis-Resistant Tumors. Pharmaceutical Research, 2012, 29, 621-636.	1.7	18
211	The chemotherapeutic agent paclitaxel inhibits autophagy through two distinct mechanisms that regulate apoptosis. Oncogene, 2013, 32, 736-746.	2.6	98
212	CDC20 overexpression predicts a poor prognosis for patients with colorectal cancer. Journal of Translational Medicine, 2013, 11, 142.	1.8	115
213	Mitosis and apoptosis: how is the balance set?. Current Opinion in Cell Biology, 2013, 25, 780-785.	2.6	155
214	Mitosis as an anti-cancer drug target. Chromosoma, 2013, 122, 431-449.	1.0	47
215	The DNA damage response during mitosis. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2013, 750, 45-55.	0.4	85
216	The causes and consequences of genetic heterogeneity in cancer evolution. Nature, 2013, 501, 338-345.	13.7	1,969
217	Single cell enzyme diagnosis on the chip. , 2013, , .		1
218	Characterization of novel MPS1 inhibitors with preclinical anticancer activity. Cell Death and Differentiation, 2013, 20, 1532-1545.	5.0	88
219	Determinants of robustness in spindle assembly checkpoint signalling. Nature Cell Biology, 2013, 15, 1328-1339.	4.6	92

#	Article	IF	Citations
220	DNA damage associated with mitosis and cytokinesis failure. Oncogene, 2013, 32, 4593-4601.	2.6	134
221	Genetic instability: tipping the balance. Oncogene, 2013, 32, 4459-4470.	2.6	81
222	Does androgenâ€ablation therapy (<scp>AAT</scp>) associated autophagy have a proâ€survival effect in <scp>LNCaP</scp> human prostate cancer cells?. BJU International, 2013, 111, 672-682.	1.3	32
223	Mitotic Control of Cancer Stem Cells. Cancer Discovery, 2013, 3, 141-144.	7.7	7
224	2n or not 2n: Aneuploidy, polyploidy and chromosomal instability in primary and tumor cells. Seminars in Cell and Developmental Biology, 2013, 24, 370-379.	2.3	83
225	NEK9 depletion induces catastrophic mitosis by impairment of mitotic checkpoint control and spindle dynamics. Biochemical and Biophysical Research Communications, 2013, 442, 139-146.	1.0	29
226	Monitoring tumor response with [18F]FMAU in a sarcoma-bearing mouse model after liposomal vinorelbine treatment. Nuclear Medicine and Biology, 2013, 40, 1035-1042.	0.3	1
227	Protein Aggregation Behavior Regulates Cyclin Transcript Localization and Cell-Cycle Control. Developmental Cell, 2013, 25, 572-584.	3.1	103
228	The cancer biology of whole-chromosome instability. Oncogene, 2013, 32, 4727-4736.	2.6	106
229	Making an effective switch at the kinetochore by phosphorylation and dephosphorylation. Chromosoma, 2013, 122, 135-158.	1.0	115
230	Microfluidic Chemical Cytometry of Peptide Degradation in Single Drug-Treated Acute Myeloid Leukemia Cells. Analytical Chemistry, 2013, 85, 4991-4997.	3.2	25
231	High-Throughput Secretomic Analysis of Single Cells to Assess Functional Cellular Heterogeneity. Analytical Chemistry, 2013, 85, 2548-2556.	3.2	156
232	Beyond genetics in personalized cancer treatment: assessing dynamics and heterogeneity of tumor responses. Personalized Medicine, 2013, 10, 221-225.	0.8	5
233	Fast Metabolic Response to Drug Intervention Through Analysis on a Miniaturized, Highly Integrated Molecular Imaging System. Journal of Nuclear Medicine, 2013, 54, 1820-1824.	2.8	10
234	Single-cell protein secretomic signatures as potential correlates to tumor cell lineage evolution and cellâ€“cell interaction. Frontiers in Oncology, 2013, 3, 10.	1.3	8
235	Dynamic Rendering of the Heterogeneous Cell Response to Anticancer Treatments. PLoS Computational Biology, 2013, 9, e1003293.	1.5	12
236	Targeting mitotic exit with hyperthermia or APC/C inhibition to increase paclitaxel efficacy. Cell Cycle, 2013, 12, 2598-2607.	1.3	43
237	Modulating cell-to-cell variability and sensitivity to death ligands by co-drugging. Physical Biology, 2013, 10, 035002.	0.8	19

#	Article	IF	Citations
238	A Double-Edged Sword: How Oncogenes and Tumor Suppressor Genes Can Contribute to Chromosomal Instability. Frontiers in Oncology, 2013, 3, 164.	1.3	56
239	The spindle assembly checkpoint works like a rheostat rather than a toggle switch. Nature Cell Biology, 2013, 15, 1378-1385.	4.6	192
240	SGOL1 variant B induces abnormal mitosis and resistance to taxane in non-small cell lung cancers. Scientific Reports, 2013, 3, 3012.	1.6	26
241	The MAD1 1673 Gâ†'A polymorphism alters the function of the mitotic spindle assembly checkpoint and is associated with a worse response to induction chemotherapy and sensitivity to treatment in patients with advanced epithelial ovarian cancer. Pharmacogenetics and Genomics, 2013, 23, 190-199.	0.7	9
242	BubR1 is frequently repressed in acute myeloid leukemia and its re-expression sensitizes cells to antimitotic therapy. Haematologica, 2013, 98, 1886-1895.	1.7	21
243	Identifying and Quantifying Heterogeneity in High Content Analysis: Application of Heterogeneity Indices to Drug Discovery. PLoS ONE, 2014, 9, e102678.	1.1	50
244	Plk1 Inhibition Causes Post-Mitotic DNA Damage and Senescence in a Range of Human Tumor Cell Lines. PLoS ONE, 2014, 9, e111060.	1.1	36
245	Cyclin B1 Overexpression Induces Cell Death Independent of Mitotic Arrest. PLoS ONE, 2014, 9, e113283.	1.1	19
246	HSP90 Inhibition Enhances Antimitotic Drug-Induced Mitotic Arrest and Cell Death in Preclinical Models of Non-Small Cell Lung Cancer. PLoS ONE, 2014, 9, e115228.	1.1	14
247	Single cell transcriptional analysis reveals novel innate immune cell types. PeerJ, 2014, 2, e452.	0.9	11
248	Partial inhibition of Cdk1 in G₂phase overrides the SAC and decouples mitotic events. Cell Cycle, 2014, 13, 1400-1412.	1.3	773
249	Chk1 inhibition in p53-deficient cell lines drives rapid chromosome fragmentation followed by caspase-independent cell death. Cell Cycle, 2014, 13, 303-314.	1.3	34
250	A novel synthetic 1,3-phenyl bis-thiourea compound targets microtubule polymerization to cause cancer cell death. Cancer Biology and Therapy, 2014, 15, 895-905.	1.5	25
251	Bcl-xL controls a switch between cell death modes during mitotic arrest. Cell Death and Disease, 2014, 5, e1291-e1291.	2.7	52
252	Post-slippage multinucleation renders cytotoxic variation in anti-mitotic drugs that target the microtubules or mitotic spindle. Cell Cycle, 2014, 13, 1756-1764.	1.3	52
253	Quantitative multi-parametric evaluation of centrosome declustering drugs: centrosome amplification, mitotic phenotype, cell cycle and death. Cell Death and Disease, 2014, 5, e1204-e1204.	2.7	26
254	An Overview of the Spindle Assembly Checkpoint Status in Oral Cancer. BioMed Research International, 2014, 2014, 1-8.	0.9	13
255	Genotoxic Anti-Cancer Agents and Their Relationship to DNA Damage, Mitosis, and Checkpoint Adaptation in Proliferating Cancer Cells. International Journal of Molecular Sciences, 2014, 15, 3403-3431.	1.8	155

#	Article	IF	Citations
256	Stressing Mitosis to Death. Frontiers in Oncology, 2014, 4, 140.	1.3	39
257	Homeostatic control of polo-like kinase-1 engenders non-genetic heterogeneity in G2 checkpoint fidelity and timing. Nature Communications, 2014, 5, 4048.	5.8	42
258	Phospho-Bcl-xL(Ser62) influences spindle assembly and chromosome segregation during mitosis. Cell Cycle, 2014, 13, 1313-1326.	1.3	6
259	Single-Cell Western Blotting after Whole-Cell Imaging to Assess Cancer Chemotherapeutic Response. Analytical Chemistry, 2014, 86, 10429-10436.	3.2	88
260	<scp>SIRT</scp>2 knockdown increases basal autophagy and prevents postslippage death by abnormally prolonging the mitotic arrest that is induced by microtubule inhibitors. FEBS Journal, 2014, 281, 2623-2637.	2.2	51
261	COH-203, a novel microtubule inhibitor, exhibits potent anti-tumor activity via p53-dependent senescence in hepatocellular carcinoma. Biochemical and Biophysical Research Communications, 2014, 455, 262-268.	1.0	11
262	Revitalizing Personalized Medicine: Respecting Biomolecular Complexities Beyond Gene Expression. CPT: Pharmacometrics and Systems Pharmacology, 2014, 3, 1-11.	1.3	5
263	Cytotoxicity of Paclitaxel in Breast Cancer Is due to Chromosome Missegregation on Multipolar Spindles. Science Translational Medicine, 2014, 6, 229ra43.	5.8	298
264	The taccalonolides and paclitaxel cause distinct effects on microtubule dynamics and aster formation. Molecular Cancer, 2014, 13, 41.	7.9	28
265	High <scp>CDC</scp>20 expression is associated with poor prognosis in oral squamous cell carcinoma. Journal of Oral Pathology and Medicine, 2014, 43, 225-231.	1.4	54
266	Interaction of standardized mistletoe (Viscum album) extracts with chemotherapeutic drugs regarding cytostatic and cytotoxic effects in vitro. BMC Complementary and Alternative Medicine, 2014, 14, 6.	3.7	41
267	Evolution of the Cancer Stem Cell Model. Cell Stem Cell, 2014, 14, 275-291.	5.2	1,825
268	Quantitative study of cellular heterogeneity in doxorubicin uptake and its pharmacological effect on cancer cells. Biomedical Chromatography, 2014, 28, 1393-1401.	0.8	8
269	BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling. Oncogene, 2014, 33, 1418-1428.	2.6	43
270	Mechanisms Promoting Escape from Mitotic Stressâ€“Induced Tumor Cell Death. Cancer Research, 2014, 74, 3857-3869.	0.4	31
271	How Taxol/paclitaxel kills cancer cells. Molecular Biology of the Cell, 2014, 25, 2677-2681.	0.9	1,033
272	Response of single leukemic cells to peptidase inhibitor therapy across time and dose using a microfluidic device. Integrative Biology (United Kingdom), 2014, 6, 164-174.	0.6	11
273	Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines. Endocrine-Related Cancer, 2014, 21, 797-811.	1.6	28

#	Article	IF	Citations
274	Genomeâ€wide si RNA screen reveals coupling between mitotic apoptosis and adaptation. EMBO Journal, 2014, 33, 1960-1976.	3.5	39
275	Stop competing, start talking!. EMBO Journal, 2014, 33, 1849-1851.	3.5	5
276	Translational Exposureâ€“Efficacy Modeling to Optimize the Dose and Schedule of Taxanes Combined with the Investigational Aurora A Kinase Inhibitor MLN8237 (Alisertib). Molecular Cancer Therapeutics, 2014, 13, 2170-2183.	1.9	29
277	Evaluation of 2â€²,4â€²-dihydroxy-3,4,5-trimethoxychalcone as antimitotic agent that induces mitotic catastrophe in MCF-7 breast cancer cells. Toxicology Letters, 2014, 229, 393-401.	0.4	23
278	Cdh1 is an antagonist of the spindle assembly checkpoint. Cellular Signalling, 2014, 26, 2217-2222.	1.7	7
279	Aurea Mediocritas: The Importance of a Balanced Genome. Cold Spring Harbor Perspectives in Biology, 2014, 6, a015842-a015842.	2.3	19
280	Toward understanding ubiquitin-modifying enzymes: from pharmacological targeting to proteomics. Trends in Pharmacological Sciences, 2014, 35, 187-207.	4.0	40
281	Aurora Kinase Inhibition As an Anticancer Strategy. Journal of Clinical Oncology, 2014, 32, 57-59.	0.8	50
282	AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs. Cancer Research, 2014, 74, 5878-5890.	0.4	137
283	Phosphorylation of the Proapoptotic BH3-Only Protein Bid Primes Mitochondria for Apoptosis during Mitotic Arrest. Cell Reports, 2014, 7, 661-671.	2.9	34
284	Microcephaly disease gene Wdr62 regulates mitotic progression of embryonic neural stem cells and brain size. Nature Communications, 2014, 5, 3885.	5.8	130
285	Inhibiting tumor growth by targeting liposomally encapsulated CDC20siRNA to tumor vasculature: Therapeutic RNA interference. Journal of Controlled Release, 2014, 180, 100-108.	4.8	41
286	Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function. Bioorganic and Medicinal Chemistry, 2014, 22, 5050-5059.	1.4	204
287	APCCdc20 Suppresses Apoptosis through Targeting Bim for Ubiquitination and Destruction. Developmental Cell, 2014, 29, 377-391.	3.1	110
288	Update on Adjuvant Chemotherapy for Early Breast Cancer. Breast Cancer: Basic and Clinical Research, 2014, 8, BCBCR.S9454.	0.6	33
289	On comparing heterogeneity across biomarkers. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2015, 87, 558-567.	1.1	12
290	Cellular responses to a prolonged delay in mitosis are determined by a DNA damage response controlled by Bcl-2 family proteins. Open Biology, 2015, 5, 140156.	1.5	42
291	The lethal response to Cdk1 inhibition depends on sister chromatid alignment errors generated by KIF4 and isoform 1 of PRC1. Scientific Reports, 2015, 5, 14798.	1.6	25

#	Article	IF	Citations
292	Longitudinal tracking of single live cancer cells to understand cell cycle effects of the nuclear export inhibitor, selinexor. Scientific Reports, 2015, 5, 14391.	1.6	24
293	Synthetic lethality and chemoresistance in cancer. , 0, , 65-82.		0
294	Integrating Multiscale Modeling with Drug Effects for Cancer Treatment. Cancer Informatics, 2015, 14s5, CIN.S30797.	0.9	10
295	Lifetime Distributions from Tracking Individual BC3H1 Cells Subjected to Yessotoxin. Frontiers in Bioengineering and Biotechnology, 2015, 3, 166.	2.0	9
296	Targeting the Mitotic Catastrophe Signaling Pathway in Cancer. Mediators of Inflammation, 2015, 2015, 1-13.	1.4	148
297	Inhibition of Bcl-xL overcomes polyploidy resistance and leads to apoptotic cell death in acute myeloid leukemia cells. Oncotarget, 2015, 6, 21557-21571.	0.8	25
298	Splicing function of mitotic regulators links R-loopâ€“mediated DNA damage to tumor cell killing. Journal of Cell Biology, 2015, 209, 235-246.	2.3	57
299	A novel anti-microtubule agent with carbazole and benzohydrazide structures suppresses tumor cell growth in vivo. Biochimica Et Biophysica Acta - General Subjects, 2015, 1850, 1676-1684.	1.1	9
300	Phosphorylation of SAF-A/hnRNP-U Serine 59 by Polo-Like Kinase 1 Is Required for Mitosis. Molecular and Cellular Biology, 2015, 35, 2699-2713.	1.1	17
301	The selective inhibition of protein phosphatase-1 results in mitotic catastrophe and impaired tumor growth. Journal of Cell Science, 2015, 128, 4526-37.	1.2	29
302	The complexity of life and death decisions in mitosis. Molecular and Cellular Oncology, 2015, 2, e969658.	0.3	1
303	Hitting the brakes: targeting microtubule motors in cancer. British Journal of Cancer, 2015, 113, 693-698.	2.9	72
304	A novel bispidinone analog induces S-phase cell cycle arrest and apoptosis in HeLa human cervical carcinoma cells. Oncology Reports, 2015, 33, 1526-1532.	1.2	9
305	Functionality of the chromosomal passenger complex in cancer. Biochemical Society Transactions, 2015, 43, 23-32.	1.6	33
306	Suppression of centrosome protein TACC3 induces G1 arrest and cell death through activation of p38â€“p53â€“p21 stress signaling pathway. European Journal of Cell Biology, 2015, 94, 90-100.	1.6	27
307	Testing Chemotherapeutic Agents in the Feather Follicle Identifies a Selective Blockade of Cell Proliferation and a Key Role for Sonic Hedgehog Signaling in Chemotherapy-Induced Tissue Damage. Journal of Investigative Dermatology, 2015, 135, 690-700.	0.3	27
308	Highly multiplexed profiling of single-cell effector functions reveals deep functional heterogeneity in response to pathogenic ligands. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E607-15.	3.3	245
309	Spatiotemporal regulation of the anaphase-promoting complex in mitosis. Nature Reviews Molecular Cell Biology, 2015, 16, 82-94.	16.1	225

#	Article	IF	Citations
310	A delay prior to mitotic entry triggers caspase 8-dependent cell death in p53-deficient Hela and HCT-116 cells. Cell Cycle, 2015, 14, 1070-1081.	1.3	3
311	Biological and Therapeutic Impact of Intratumor Heterogeneity in Cancer Evolution. Cancer Cell, 2015, 27, 15-26.	7.7	923
312	Kinesins and Cancer. , 2015, , .		16
313	Aneuploidy generates proteotoxic stress and DNA damage concurrently with p53-mediated post-mitotic apoptosis in SAC-impaired cells. Nature Communications, 2015, 6, 7668.	5.8	137
314	MYC Is a Major Determinant of Mitotic Cell Fate. Cancer Cell, 2015, 28, 129-140.	7.7	110
315	Anticancer Drugs Targeting Tubulin and Microtubules. , 2015, , 359-390.		5
316	Nek2A destruction marks APC/C activation at the prophase-to-prometaphase transition by spindle-checkpoint restricted Cdc20. Journal of Cell Science, 2015, 128, 1639-53.	1.2	16
317	Clinicopathologic significance of BubR1 and Mad2 overexpression in oral cancer. Oral Diseases, 2015, 21, 713-720.	1.5	14
318	Non-motor Spindle Proteins as Cancer Chemotherapy Targets. , 2015, , 223-249.		0
319	Down-Regulating CENP-E Activity: For Better or for Worse. , 2015, , 87-99.		2
320	The NOXAâ€“MCL1â€“BIM axis defines lifespan on extended mitotic arrest. Nature Communications, 2015, 6, 6891.	5.8	86
321	Modulation of gene expression and cell cycle by botryosphaeran, a (1â†'3)(1â†'6)-Î²-d-glucan in human lymphocytes. International Journal of Biological Macromolecules, 2015, 77, 214-221.	3.6	20
322	In vivo cell-cycle profiling in xenograft tumors by quantitative intravital microscopy. Nature Methods, 2015, 12, 577-585.	9.0	75
323	Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment. Acta Pharmacologica Sinica, 2015, 36, 1219-1227.	2.8	193
324	The Molecular Biology of Spindle Assembly Checkpoint Signaling Dynamics. Current Biology, 2015, 25, R1002-R1018.	1.8	650
325	Defective sister chromatid cohesion is synthetically lethal with impaired APC/C function. Nature Communications, 2015, 6, 8399.	5.8	46
326	MicroRNA letâ€7b regulates genomic balance by targeting Aurora B kinase. Molecular Oncology, 2015, 9, 1056-1070.	2.1	21
327	AMPK and PFKFB3 mediate glycolysis and survival inÂresponse to mitophagy during mitotic arrest. Nature Cell Biology, 2015, 17, 1304-1316.	4.6	223

#	Article	IF	Citations
329	High-throughput protease activity cytometry reveals dose-dependent heterogeneity in PMA-mediated ADAM17 activation. Integrative Biology (United Kingdom), 2015, 7, 513-524.	0.6	18
330	The Fcp1-Wee1-Cdk1 axis affects spindle assembly checkpoint robustness and sensitivity to antimicrotubule cancer drugs. Cell Death and Differentiation, 2015, 22, 1551-1560.	5.0	38
331	Delaying mitotic exit downregulates FLIP expression and strongly sensitizes tumor cells to TRAIL. Oncogene, 2015, 34, 661-669.	2.6	5
332	N-terminus-modified Hec1 suppresses tumour growth by interfering with kinetochoreâ€“microtubule dynamics. Oncogene, 2015, 34, 3325-3335.	2.6	9
333	Mitotic arrest and slippage induced by pharmacological inhibition of Poloâ€like kinase 1. Molecular Oncology, 2015, 9, 140-154.	2.1	47
334	Carcinoma-associated fibroblasts affect sensitivity to oxaliplatin and 5FU in colorectal cancer cells. Oncotarget, 2016, 7, 59766-59780.	0.8	42
335	Antiproliferative Fate of the Tetraploid Formed after Mitotic Slippage and Its Promotion; A Novel Target for Cancer Therapy Based on Microtubule Poisons. Molecules, 2016, 21, 663.	1.7	20
336	BubR1 alterations that reinforce mitotic surveillance act against aneuploidy and cancer. ELife, 2016, 5, .	2.8	15
337	Prenylated Chalcone 2 Acts as an Antimitotic Agent and Enhances the Chemosensitivity of Tumor Cells to Paclitaxel. Molecules, 2016, 21, 982.	1.7	12
338	Stage-Specific Changes in the Water, Na+, Cl- and K+ Contents of Organelles during Apoptosis, Demonstrated by a Targeted Cryo Correlative Analytical Approach. PLoS ONE, 2016, 11, e0148727.	1.1	18
339	Efficient Activation of Apoptotic Signaling during Mitotic Arrest with AK301. PLoS ONE, 2016, 11, e0153818.	1.1	7
340	CDK-1 Inhibition in G2 Stabilizes Kinetochore-Microtubules in the following Mitosis. PLoS ONE, 2016, 11, e0157491.	1.1	6
341	Cell Division Cycle 6 Promotes Mitotic Slippage and Contributes to Drug Resistance in Paclitaxel-Treated Cancer Cells. PLoS ONE, 2016, 11, e0162633.	1.1	19
342	Flubendazole induces mitotic catastrophe and senescence in colon cancer cellsin vitro. Journal of Pharmacy and Pharmacology, 2016, 68, 208-218.	1.2	35
343	Requirement for PLK1 kinase activity in the maintenance of a robust spindle assembly checkpoint. Biology Open, 2016, 5, 11-19.	0.6	31
344	Cytotoxic amounts of cisplatin induce either checkpoint adaptation or apoptosis in a concentrationâ€dependent manner in cancer cells. Biology of the Cell, 2016, 108, 127-148.	0.7	24
345	Quantitative FastFUCCI assay defines cell cycle dynamics at single-cell level. Journal of Cell Science, 2017, 130, 512-520.	1.2	53
346	Living in CIN: Mitotic Infidelity and Its Consequences for Tumor Promotion and Suppression. Developmental Cell, 2016, 39, 638-652.	3.1	121

#	Article	IF	Citations
347	Phosphorylation of XIAP by CDK1-cyclin B controls mitotic cell death. Journal of Cell Science, 2017, 130, 502-511.	1.2	11
348	Oncogenic KRAS triggers MAPK-dependent errors in mitosis and MYC-dependent sensitivity to anti-mitotic agents. Scientific Reports, 2016, 6, 29741.	1.6	17
349	Prolonged mitotic arrest induces a caspase-dependent DNA damage response at telomeres that determines cell survival. Scientific Reports, 2016, 6, 26766.	1.6	34
350	Curcumin causes DNA damage and affects associated protein expression in HeLa human cervical cancer cells. Oncology Reports, 2016, 36, 2207-2215.	1.2	41
351	A force-generating machinery maintains the spindle at the cell center during mitosis. Science, 2016, 352, 1124-1127.	6.0	138
352	c-Rel in Epidermal Homeostasis: A Spotlight on c-Rel in Cell Cycle Regulation. Journal of Investigative Dermatology, 2016, 136, 1090-1096.	0.3	7
353	Cell Cycleâ€“Dependent Mechanisms Underlie Vincristine-Induced Death of Primary Acute Lymphoblastic Leukemia Cells. Cancer Research, 2016, 76, 3553-3561.	0.4	66
354	Mitotic Catastrophe. , 2016, , 399-403.		1
355	Mitosis and mitochondrial priming for apoptosis. Biological Chemistry, 2016, 397, 595-605.	1.2	10
356	Cyclin-dependent kinase 1â€“dependent activation of APC/C ubiquitin ligase. Science, 2016, 352, 1121-1124.	6.0	92
357	Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nature Methods, 2016, 13, 521-527.	9.0	489
358	Antiproliferative activity of monastrol in human adenocarcinoma (MCF-7) and non-tumor (HB4a) breast cells. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389, 1279-1288.	1.4	7
359	Early Detection of Treatment-Induced Mitotic Arrest Using Temporal Diffusion Magnetic Resonance Spectroscopy. Neoplasia, 2016, 18, 387-397.	2.3	20
360	Difference Makers: Chromosomal Instability versus Aneuploidy in Cancer. Trends in Cancer, 2016, 2, 561-571.	3.8	60
361	Morphological single cell profiling of the epithelialâ€“mesenchymal transition. Integrative Biology (United Kingdom), 2016, 8, 1133-1144.	0.6	56
362	Modeling Tumor Growth in Animals and Humans: An Evolutionary Approach. , 2016, , 209-235.		1
363	Pseudolaric acid B induces mitotic arrest and apoptosis in both 5-fluorouracil-sensitive and -resistant colorectal cancer cells. Cancer Letters, 2016, 383, 295-308.	3.2	30
364	Inhibition of Bcl-xL sensitizes cells to mitotic blockers, but not mitotic drivers. Open Biology, 2016, 6, 160134.	1.5	28

#	Article	IF	Citations
365	Slip slidinâ€™ away of mitosis with CRL2Zyg11. Journal of Cell Biology, 2016, 215, 143-145.	2.3	1
366	A simplified Bcl-2 network model reveals quantitative determinants of cell-to-cell variation in sensitivity to anti-mitotic chemotherapeutics. Scientific Reports, 2016, 6, 36585.	1.6	4
367	Silencing of CDC20 suppresses metastatic castration-resistant prostate cancer growth and enhances chemosensitivity to docetaxel. International Journal of Oncology, 2016, 49, 1679-1685.	1.4	30
368	Paclitaxel-induced aberrant mitosis and mitotic slippage efficiently lead to proliferative death irrespective of canonical apoptosis and p53. Cell Cycle, 2016, 15, 3268-3277.	1.3	24
369	Persistence to anti-cancer treatments in the stationary to proliferating transition. Cell Cycle, 2016, 15, 3442-3453.	1.3	36
370	BUB1 and SURVIVIN proteins are not degraded after a prolonged mitosis and accumulate in the nuclei of HCT116 cells. Cell Death Discovery, 2016, 2, 16079.	2.0	4
371	Belinostat and vincristine demonstrate mutually synergistic cytotoxicity associated with mitotic arrest and inhibition of polyploidy in a preclinical model of aggressive diffuse large B cell lymphoma. Cancer Biology and Therapy, 2016, 17, 1240-1252.	1.5	25
372	Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics. Journal of Visualized Experiments, 2016, , .	0.2	9
373	A metric and workflow for quality control in the analysis of heterogeneity in phenotypic profiles and screens. Methods, 2016, 96, 12-26.	1.9	14
374	The role of phenotypic plasticity in the escape of cancer cells from targeted therapy. Biochemical Pharmacology, 2016, 122, 1-9.	2.0	34
375	Microfluidic perfusion systems for secretion fingerprint analysis of pancreatic islets: applications, challenges and opportunities. Lab on A Chip, 2016, 16, 409-431.	3.1	43
376	Centrosome amplification, chromosomal instability and cancer: mechanistic, clinical and therapeutic issues. Chromosome Research, 2016, 24, 105-126.	1.0	59
377	Quantitative imaging with Fucci and mathematics to uncover temporal dynamics of cell cycle progression. Development Growth and Differentiation, 2016, 58, 6-15.	0.6	15
378	Mechanisms and Consequences of Cancer Genome Instability: Lessons from Genome Sequencing Studies. Annual Review of Pathology: Mechanisms of Disease, 2016, 11, 283-312.	9.6	106
379	Different cell fates after mitotic slippage: From aneuploidy to polyploidy. Molecular and Cellular Oncology, 2016, 3, e1088503.	0.3	11
380	Loss of Adult Cardiac Myocyte GSK-3 Leads to Mitotic Catastrophe Resulting in Fatal Dilated Cardiomyopathy. Circulation Research, 2016, 118, 1208-1222.	2.0	92
381	Mathematical Modeling Reveals That Changes to Local Cell Density Dynamically Modulate Baseline Variations in Cell Growth and Drug Response. Cancer Research, 2016, 76, 2882-2890.	0.4	28
382	Rapid induction of apoptosis in chronic lymphocytic leukemia cells by the microtubule disrupting agent BNC105. Cancer Biology and Therapy, 2016, 17, 291-299.	1.5	20

#	Article	IF	Citations
383	Endothelial Robo4 suppresses breast cancer growth and metastasis through regulation of tumor angiogenesis. Molecular Oncology, 2016, 10, 272-281.	2.1	37
384	A comprehensive analysis of CDC20 overexpression in common malignant tumors from multiple organs: its correlation with tumor grade and stage. Tumor Biology, 2016, 37, 749-762.	0.8	65
385	The kinetochore-dependent and -independent formation of the CDC20-MAD2 complex and its functions in HeLa cells. Scientific Reports, 2017, 7, 41072.	1.6	8
386	BCL9L Dysfunction Impairs Caspase-2 Expression Permitting Aneuploidy Tolerance in Colorectal Cancer. Cancer Cell, 2017, 31, 79-93.	7.7	83
387	Anti-mitotic agents: Are they emerging molecules for cancer treatment?. , 2017, 173, 67-82.		55
388	Adaptive resistance of melanoma cells to <scp>RAF</scp> inhibition via reversible induction of a slowly dividing deâ€differentiated state. Molecular Systems Biology, 2017, 13, 905.	3.2	202
389	Biologically Relevant Heterogeneity: Metrics and Practical Insights. SLAS Discovery, 2017, 22, 213-237.	1.4	65
390	Mathematical imaging methods for mitosis analysis in live-cell phase contrast microscopy. Methods, 2017, 115, 91-99.	1.9	14
391	Aneuploidy in Cancer: Seq-ing Answers to Old Questions. Annual Review of Cancer Biology, 2017, 1, 335-354.	2.3	65
392	Suppression of spindly delays mitotic exit and exacerbates cell death response of cancer cells treated with low doses of paclitaxel. Cancer Letters, 2017, 394, 33-42.	3.2	16
393	Addressing a weakness of anticancer therapy with mitosis inhibitors: Mitotic slippage. Molecular and Cellular Oncology, 2017, 4, e1277293.	0.3	9
394	The long non-coding RNA LINC00152 is essential for cell cycle progression through mitosis in HeLa cells. Scientific Reports, 2017, 7, 2265.	1.6	51
395	Mad2 Overexpression Uncovers a Critical Role for TRIP13 in Mitotic Exit. Cell Reports, 2017, 19, 1832-1845.	2.9	38
396	Tumor-Associated Macrophages Suppress the Cytotoxic Activity of Antimitotic Agents. Cell Reports, 2017, 19, 101-113.	2.9	89
397	Microtubule Targeting Agents in Cancer Therapy: Elucidating the Underlying Molecular Mechanisms. , 2017, , 15-65.		4
398	DT-13, a saponin monomer 13 of the Dwarf lilyturf tuber, synergized with vinorelbine to induce mitotic arrest via activation of ERK signaling pathway in NCI-H1299 cells. Biomedicine and Pharmacotherapy, 2017, 89, 1277-1285.	2.5	12
399	Dual recognition of chromatin and microtubules by INCENP is important for mitotic progression. Journal of Cell Biology, 2017, 216, 925-941.	2.3	36
400	Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinic. Endocrine-Related Cancer, 2017, 24, T83-T96.	1.6	63

#	Article	IF	Citations
401	Trichodermin induces c-Jun N-terminal kinase-dependent apoptosis caused by mitotic arrest and DNA damage in human p53-mutated pancreatic cancer cells and xenografts. Cancer Letters, 2017, 388, 249-261.	3.2	17
402	The Spindle Assembly Checkpoint in Arabidopsis Is Rapidly Shut Off during Severe Stress. Developmental Cell, 2017, 43, 172-185.e5.	3.1	61
403	CyclinG1 Amplification Enhances Aurora Kinase Inhibitor-Induced Polyploid Resistance and Inhibition of Bcl-2 Pathway Reverses the Resistance. Cellular Physiology and Biochemistry, 2017, 43, 94-107.	1.1	13
404	Computational Cell Cycle Profiling of Cancer Cells for Prioritizing FDA-Approved Drugs with Repurposing Potential. Scientific Reports, 2017, 7, 11261.	1.6	27
405	Induction of accelerated senescence by the microtubule-stabilizing agent peloruside A. Investigational New Drugs, 2017, 35, 706-717.	1.2	11
406	A confidence building exercise in data and identifiability: Modeling cancer chemotherapy as a case study. Journal of Theoretical Biology, 2017, 431, 63-78.	0.8	52
407	Role of chromosomal instability in cancer progression. Endocrine-Related Cancer, 2017, 24, T23-T31.	1.6	67
408	How to address cellular heterogeneity by distribution biology. Current Opinion in Systems Biology, 2017, 3, 154-160.	1.3	30
409	The responses of cancer cells to PLK1 inhibitors reveal a novel protective role for p53 in maintaining centrosome separation. Scientific Reports, 2017, 7, 16115.	1.6	27
410	Is inflammatory micronucleation the key to a successful anti-mitotic cancer drug?. Open Biology, 2017, 7, 170182.	1.5	61
411	Taming the Beast: Control of APC/C^{Cdc20}-Dependent Destruction. Cold Spring Harbor Symposia on Quantitative Biology, 2017, 82, 111-121.	2.0	9
412	Precocious centriole disengagement and centrosome fragmentation induced by mitotic delay. Nature Communications, 2017, 8, 15803.	5.8	24
413	Consequences of mitotic slippage for antimicrotubule drug therapy. Endocrine-Related Cancer, 2017, 24, T97-T106.	1.6	64
414	Sensitivity to antitubulin chemotherapeutics is potentiated by a photoactivable nanoliposome. Biomaterials, 2017, 141, 50-62.	5.7	37
415	Rhodium metalloinsertor binding generates a lesion with selective cytotoxicity for mismatch repair-deficient cells. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 6948-6953.	3.3	12
416	IL-33 fine tunes mast cell degranulation and chemokine production at the single-cell level. Journal of Allergy and Clinical Immunology, 2017, 140, 497-509.e10.	1.5	80
417	Microtubule destabilising agents: far more than just antimitotic anticancer drugs. British Journal of Clinical Pharmacology, 2017, 83, 255-268.	1.1	237
418	Mitotic slippage and the subsequent cell fates after inhibition of Aurora B during tubulin-binding agentâ€“induced mitotic arrest. Scientific Reports, 2017, 7, 16762.	1.6	32

#	Article	IF	Citations
419	Mitotic Catastrophe in BC3H1 Cells following Yessotoxin Exposure. Frontiers in Cell and Developmental Biology, 2017, 5, 30.	1.8	12
420	The Consequences of Chromosome Segregation Errors in Mitosis and Meiosis. Biology, 2017, 6, 12.	1.3	118
421	Modeling Cancer Cell Growth Dynamics In vitro in Response to Antimitotic Drug Treatment. Frontiers in Oncology, 2017, 7, 189.	1.3	13
422	Molecular Regulation of the Spindle Assembly Checkpoint by Kinases and Phosphatases. International Review of Cell and Molecular Biology, 2017, 328, 105-161.	1.6	38
423	The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome. BMC Medicine, 2017, 15, 133.	2.3	166
424	Identification of pyrrolopyrimidine derivative PP-13 as a novel microtubule-destabilizing agent with promising anticancer properties. Scientific Reports, 2017, 7, 10209.	1.6	16
425	Preclinical activity of DCZ3301, a novel aryl-guanidino compound in the therapy of multiple myeloma. Theranostics, 2017, 7, 3690-3699.	4.6	12
426	Perturbing mitosis for antiâ€cancer therapy: is cell death the only answer?. EMBO Reports, 2018, 19, .	2.0	67
427	Integrating Analysis of Cellular Heterogeneity in High-Content Dose-Response Studies. Methods in Molecular Biology, 2018, 1745, 25-46.	0.4	0
428	Analysis of Microtubule Dynamics Heterogeneity in Cell Culture. Methods in Molecular Biology, 2018, 1745, 181-204.	0.4	3
429	Anti-mitotic chemotherapeutics promote apoptosis through TL1A-activated death receptor 3 in cancer cells. Cell Research, 2018, 28, 544-555.	5.7	31
430	Quantitative proteomic and phosphoproteomic comparison of human colon cancer DLD-1 cells differing in ploidy and chromosome stability. Molecular Biology of the Cell, 2018, 29, 1031-1047.	0.9	41
431	Mammalian Cells Undergo Endoreduplication in Response to Lactic Acidosis. Scientific Reports, 2018, 8, 2890.	1.6	10
432	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death and Differentiation, 2018, 25, 486-541.	5.0	4,036
433	In vitro characterization of alkylaminophenols-induced cell death. European Journal of Pharmacology, 2018, 820, 229-234.	1.7	4
434	The impact of non-genetic heterogeneity on cancer cell death. Critical Reviews in Biochemistry and Molecular Biology, 2018, 53, 99-114.	2.3	41
435	Experimental Determination of Checkpoint Adaptation byÂMitotic Shake-Off and Microscopy. Methods in Molecular Biology, 2018, 1769, 159-168.	0.4	2
436	Biological activity of dihydropyrimidinone (DHPM) derivatives: A systematic review. European Journal of Medicinal Chemistry, 2018, 143, 1779-1789.	2.6	143

#	Article	IF	Citations
437	Molecular mechanism of action of oxazolinoanthracyclines in cells derived from human solid tumors. Part 2. Toxicology in Vitro, 2018, 46, 323-334.	1.1	7
438	Label-free visualization and quantification of single cell signaling activity using metal-clad waveguide (MCWG)-based microscopy. Biosensors and Bioelectronics, 2018, 100, 429-436.	5.3	10
439	A fine balancing act: A delicate kinase-phosphatase equilibrium that protects against chromosomal instability and cancer. International Journal of Biochemistry and Cell Biology, 2018, 96, 148-156.	1.2	23
440	Enzyme-Free Nucleic Acid Amplification Assay Using a Cellphone-Based Well Plate Fluorescence Reader. Analytical Chemistry, 2018, 90, 690-695.	3.2	27
441	A single-cell micro-trench platform for automatic monitoring of cell division and apoptosis after chemotherapeutic drug administration. Scientific Reports, 2018, 8, 18042.	1.6	5
442	Chromosome instability in tumor cells due to defects in Aurora B mediated error correction at kinetochores. Cell Cycle, 2018, 17, 2622-2636.	1.3	12
443	Selective Degradation of Poloâ€like Kinase 1 by a Hydrophobically Tagged Inhibitor of the Poloâ€Box Domain. Angewandte Chemie, 2018, 130, 17289-17293.	1.6	3
444	Lipid accumulation facilitates mitotic slippage-induced adaptation to anti-mitotic drug treatment. Cell Death Discovery, 2018, 4, 109.	2.0	14
445	Inhibition of kinesin family member 20B sensitizes hepatocellular carcinoma cell to microtubuleâ€targeting agents by blocking cytokinesis. Cancer Science, 2018, 109, 3450-3460.	1.7	21
446	Implications of alternative routes to APC/C inhibition by the mitotic checkpoint complex. PLoS Computational Biology, 2018, 14, e1006449.	1.5	6
447	Analysis of the role of GSK3 in the mitotic checkpoint. Scientific Reports, 2018, 8, 14259.	1.6	19
448	Selective Degradation of Poloâ€like Kinase 1 by a Hydrophobically Tagged Inhibitor of the Poloâ€Box Domain. Angewandte Chemie - International Edition, 2018, 57, 17043-17047.	7.2	24
449	CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response. Nature Communications, 2018, 9, 4275.	5.8	56
450	The tyrosine kinase v-Src causes mitotic slippage by phosphorylating an inhibitory tyrosine residue of Cdk1. Journal of Biological Chemistry, 2018, 293, 15524-15537.	1.6	21
451	Protocols for the Study of Taxanes Chemosensitivity in Prostate Cancer. Methods in Molecular Biology, 2018, 1786, 153-173.	0.4	2
453	The impact of mitotic errors on cell proliferation and tumorigenesis. Genes and Development, 2018, 32, 620-638.	2.7	177
454	Mitotic live-cell imaging at different timescales. Methods in Cell Biology, 2018, 145, 1-27.	0.5	8
455	Universal response in the RKO colon cancer cell line to distinct antimitotic therapies. Scientific Reports, 2018, 8, 8979.	1.6	2

#	Article	IF	Citations
456	Spindle assembly checkpoint strength is linked to cell fate in theCaenorhabditis elegansembryo. Molecular Biology of the Cell, 2018, 29, 1435-1448.	0.9	21
457	Autophagy Governs Protumorigenic Effects of Mitotic Slippageâ€“induced Senescence. Molecular Cancer Research, 2018, 16, 1625-1640.	1.5	23
458	Atypical APC/Câ€dependent degradation of Mclâ€1 provides an apoptotic timer during mitotic arrest. EMBO Journal, 2018, 37, .	3.5	32
459	Microtubules play an essential role in the survival of primary acute lymphoblastic leukemia cells advancing through G1 phase. Cell Cycle, 2018, 17, 1784-1796.	1.3	6
460	Reducing protein regulator of cytokinesis 1 as a prospective therapy for hepatocellular carcinoma. Cell Death and Disease, 2018, 9, 534.	2.7	48
461	Viability Assessment Following Anticancer Treatment Requires Single-Cell Visualization. Cancers, 2018, 10, 255.	1.7	21
462	Activation of the apoptotic pathway during prolonged prometaphase blocks daughter cell proliferation. Molecular Biology of the Cell, 2018, 29, 2632-2643.	0.9	12
463	Geraniin selectively promotes cytostasis and apoptosis in human colorectal cancer cells by inducing catastrophic chromosomal instability. Mutagenesis, 2018, 33, 271-281.	1.0	21
464	Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel. Journal of Visualized Experiments, 2018, , .	0.2	5
465	Assays for the spindle assembly checkpoint in cell culture. Methods in Cell Biology, 2018, 144, 1-13.	0.5	4
466	Mild replication stress causes chromosome mis-segregation via premature centriole disengagement. Nature Communications, 2019, 10, 3585.	5.8	92
467	A general approach for detecting expressed mutations in AML cells using single cell RNA-sequencing. Nature Communications, 2019, 10, 3660.	5.8	147
468	Vincristine-loaded platelets coated with anti-CD41 mAbs: a new macrophage targeting proposal for the treatment of immune thrombocytopenia. Biomaterials Science, 2019, 7, 4568-4577.	2.6	12
469	The Cytoplasmic DNA Sensor cGAS Promotes Mitotic Cell Death. Cell, 2019, 178, 302-315.e23.	13.5	267
470	Reorganization of paclitaxel-stabilized microtubule arrays at mitotic entry: roles of depolymerizing kinesins and severing proteins. Cancer Biology and Therapy, 2019, 20, 1337-1347.	1.5	21
471	M2I-1 disrupts the in vivo interaction between CDC20 and MAD2 and increases the sensitivities of cancer cell lines to anti-mitotic drugs via MCL-1s. Cell Division, 2019, 14, 5.	1.1	8
472	Upregulation of Myt1 Promotes Acquired Resistance of Cancer Cells to Wee1 Inhibition. Cancer Research, 2019, 79, 5971-5985.	0.4	40
473	A novel strategy to block mitotic progression for targeted therapy. EBioMedicine, 2019, 49, 40-54.	2.7	33

#	Article	IF	Citations
474	Proteomics advances for precision therapy in ovarian cancer. Expert Review of Proteomics, 2019, 16, 841-850.	1.3	5
475	Synergistic effect of a retinoid X receptor-selective ligand bexarotene and docetaxel in prostate cancer . OncoTargets and Therapy, 2019, Volume 12, 7877-7886.	1.0	5
476	Single-Cell Screening of Tamoxifen Abundance and Effect Using Mass Spectrometry and Raman-Spectroscopy. Analytical Chemistry, 2019, 91, 2710-2718.	3.2	27
477	Regulated Cell Death Signaling Pathways and Marine Natural Products That Target Them. Marine Drugs, 2019, 17, 76.	2.2	20
478	Mapping Mitotic Death: Functional Integration of Mitochondria, Spindle Assembly Checkpoint and Apoptosis. Frontiers in Cell and Developmental Biology, 2018, 6, 177.	1.8	29
479	Towards modern anticancer agents that interact with tubulin. European Journal of Pharmaceutical Sciences, 2019, 131, 58-68.	1.9	34
480	Identification of the potential therapeutic target gene UBE2C in human hepatocellular carcinoma: An investigation based on GEO and TCGA databases. Oncology Letters, 2019, 17, 5409-5418.	0.8	21
481	Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review. Cancer Chemotherapy and Pharmacology, 2019, 84, 471-485.	1.1	71
482	Mechanisms of Genomic Instability in Breast Cancer. Trends in Molecular Medicine, 2019, 25, 595-611.	3.5	109
483	Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability. Neoplasia, 2019, 21, 363-375.	2.3	27
484	Extensive epigenetic and transcriptomic variability between genetically identical human B-lymphoblastoid cells with implications in pharmacogenomics research. Scientific Reports, 2019, 9, 4889.	1.6	18
485	Imbalance of the spindle-assembly checkpoint promotes spindle poison-mediated cytotoxicity with distinct kinetics. Cell Death and Disease, 2019, 10, 314.	2.7	12
486	Resistance to anti-microtubule drug-induced cell death is determined by regulation of BimEL expression. Oncogene, 2019, 38, 4352-4365.	2.6	2
487	Cell-Size-Independent Spindle Checkpoint Failure Underlies Chromosome Segregation Error in Mouse Embryos. Current Biology, 2019, 29, 865-873.e3.	1.8	49
488	Cellular response upon proliferation in the presence of an active mitotic checkpoint. Life Science Alliance, 2019, 2, e201900380.	1.3	2
489	MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma. Blood Advances, 2019, 3, 1185-1196.	2.5	19
490	The LIV-1-GRPEL1 axis adjusts cell fate during anti-mitotic agent-damaged mitosis. EBioMedicine, 2019, 49, 26-39.	2.7	3
491	The balance between mitotic death and mitotic slippage in acute leukemia: a new therapeutic window?. Journal of Hematology and Oncology, 2019, 12, 123.	6.9	27

#	Article	IF	Citations
492	Mitotic slippage: an old tale with a new twist. Cell Cycle, 2019, 18, 7-15.	1.3	81
493	Geraniin Differentially Modulates Chromosome Stability of Colon Cancer and Noncancerous Cells by Oppositely Regulating their Spindle Assembly Checkpoint. Environmental and Molecular Mutagenesis, 2019, 60, 254-268.	0.9	13
494	Targeting mitosis exit: A brake for cancer cell proliferation. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 179-191.	3.3	42
495	MYC-Induced miR-203b-3p and miR-203a-3p Control Bcl-xL Expression and Paclitaxel Sensitivity in Tumor Cells. Translational Oncology, 2019, 12, 170-179.	1.7	29
496	Environmental stresses induce karyotypic instability in colorectal cancer cells. Molecular Biology of the Cell, 2019, 30, 42-55.	0.9	22
497	Mitosis inhibitors in anticancer therapy: When blocking the exit becomes a solution. Cancer Letters, 2019, 440-441, 64-81.	3.2	60
498	Cytokinesis defects and cancer. Nature Reviews Cancer, 2019, 19, 32-45.	12.8	176
499	Heat shockâ€induced mitotic arrest requires heat shock protein 105 for the activation of spindle assembly checkpoint. FASEB Journal, 2019, 33, 3936-3953.	0.2	11
500	Combining fluorescent cell barcoding and flow cytometryâ€based phosphoâ€ERK1/2 detection at short time scales in adherent cells. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2019, 95, 192-200.	1.1	11
501	CKT0353, a novel microtubule targeting agent, overcomes paclitaxel induced resistance in cancer cells. Investigational New Drugs, 2020, 38, 584-598.	1.2	4
502	Advanced technological tools to study multidrug resistance in cancer. Drug Resistance Updates, 2020, 48, 100658.	6.5	48
503	FBXO45-MYCBP2 regulates mitotic cell fate by targeting FBXW7 for degradation. Cell Death and Differentiation, 2020, 27, 758-772.	5.0	27
504	Boosting the apoptotic response of highâ€grade serous ovarian cancers with CCNE1 amplification to paclitaxel in vitro by targeting APC/C and the proâ€survival protein MCLâ€1. International Journal of Cancer, 2020, 146, 1086-1098.	2.3	29
505	Cell-Cycle Cross Talk with Caspases and Their Substrates. Cold Spring Harbor Perspectives in Biology, 2020, 12, a036475.	2.3	17
506	Identifying fates of cancer cells exposed to mitotic inhibitors by quantitative phase imaging. Analyst, The, 2020, 145, 97-106.	1.7	9
507	BioID-based proteomic analysis of the Bid interactome identifies novel proteins involved in cell-cycle-dependent apoptotic priming. Cell Death and Disease, 2020, 11, 872.	2.7	6
508	The mTORC1/S6K/PDCD4/eIF4A Axis Determines Outcome of Mitotic Arrest. Cell Reports, 2020, 33, 108230.	2.9	17
509	The Negative Cross-Talk between SAG/RBX2/ROC2 and APC/C E3 Ligases in Regulation of Cell Cycle Progression and Drug Resistance. Cell Reports, 2020, 32, 108102.	2.9	10

#	Article	IF	Citations
510	Phosphodiesterase Type 5 Inhibitors Synergize Vincristine in Killing Castration-Resistant Prostate Cancer Through Amplifying Mitotic Arrest Signaling. Frontiers in Oncology, 2020, 10, 1274.	1.3	14
511	Release from cell cycle arrest with Cdk4/6 inhibitors generates highly synchronized cell cycle progression in human cell culture. Open Biology, 2020, 10, 200200.	1.5	27
512	Targeting of BCL-2 Family Members during Anticancer Treatment: A Necessary Compromise between Individual Cell and Ecosystemic Responses?. Biomolecules, 2020, 10, 1109.	1.8	4
513	Disentangling the behavioural variability of confined cell migration. Journal of the Royal Society Interface, 2020, 17, 20190689.	1.5	21
514	APC/C ubiquitin ligase: Functions and mechanisms in tumorigenesis. Seminars in Cancer Biology, 2020, 67, 80-91.	4.3	57
515	Paradoxical mitotic exit induced by a small molecule inhibitor of APC/CCdc20. Nature Chemical Biology, 2020, 16, 546-555.	3.9	16
516	Drp1 modulates mitochondrial stress responses to mitotic arrest. Cell Death and Differentiation, 2020, 27, 2620-2634.	5.0	18
517	Mitotic stress-induced secretome primes cancer cells to apoptosis and maximizes paclitaxel response in breast tumors when combined with BCL-xL-targeting BH3 mimetics. Molecular and Cellular Oncology, 2020, 7, 1735912.	0.3	1
518	Protein level variability determines phenotypic heterogeneity in proteotoxic stress response. FEBS Journal, 2020, 287, 5345-5361.	2.2	11
519	Mitotic slippage is determined by p31comet and the weakening of the spindle-assembly checkpoint. Oncogene, 2020, 39, 2819-2834.	2.6	23
520	A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity. Nature Communications, 2020, 11, 822.	5.8	62
521	Molecular Mechanisms of Radiation-Induced Cancer Cell Death: A Primer. Frontiers in Cell and Developmental Biology, 2020, 8, 41.	1.8	203
522	Phenotype-based probabilistic analysis of heterogeneous responses to cancer drugs and their combination efficacy. PLoS Computational Biology, 2020, 16, e1007688.	1.5	16
523	BAD sensitizes breast cancer cells to docetaxel with increased mitotic arrest and necroptosis. Scientific Reports, 2020, 10, 355.	1.6	30
524	The Phosphatase PP1 Promotes Mitotic Slippage through Mad3 Dephosphorylation. Current Biology, 2020, 30, 335-343.e5.	1.8	7
525	STING-dependent paracriny shapes apoptotic priming of breast tumors in response to anti-mitotic treatment. Nature Communications, 2020, 11, 259.	5.8	65
526	The microtubule targeting agents eribulin and paclitaxel activate similar signaling pathways and induce cell death predominantly in a caspase-independent manner. Cell Cycle, 2020, 19, 464-478.	1.3	15
527	MARCH5-dependent degradation of MCL1/NOXA complexes defines susceptibility to antimitotic drug treatment. Cell Death and Differentiation, 2020, 27, 2297-2312.	5.0	31

#	Article	IF	Citations
528	Separase-triggered apoptosis enforces minimal length of mitosis. Nature, 2020, 580, 542-547.	13.7	26
529	The antiâ€mitotic agents PTCâ€028 and PTC596 display potent activity in preâ€clinical models of multiple myeloma but challenge the role of BMIâ€1 as an essential tumour gene. British Journal of Haematology, 2020, 190, 877-890.	1.2	15
530	p53 Is Not Required for High CIN to Induce Tumor Suppression. Molecular Cancer Research, 2021, 19, 112-123.	1.5	11
531	Predicting and Overcoming Taxane Chemoresistance. Trends in Molecular Medicine, 2021, 27, 138-151.	3.5	16
532	10-(4-Phenylpiperazine-1-carbonyl)acridin-9(10H)-ones and related compounds: Synthesis, antiproliferative activity and inhibition of tubulin polymerization. Bioorganic and Medicinal Chemistry Letters, 2021, 32, 127687.	1.0	2
533	Eg5 targeting agents: From new anti-mitotic based inhibitor discovery to cancer therapy and resistance. Biochemical Pharmacology, 2021, 184, 114364.	2.0	54
534	Taxanes in cancer treatment: Activity, chemoresistance and its overcoming. Drug Resistance Updates, 2021, 54, 100742.	6.5	121
535	Depletion of Survivin suppresses docetaxel-induced apoptosis in HeLa cells by facilitating mitotic slippage. Scientific Reports, 2021, 11, 2283.	1.6	9
536	The Mad2-Binding Protein p31comet as a potential target for human cancer therapy. Current Cancer Drug Targets, 2021, 21, 401-415.	0.8	1
537	Mitotic checkpoint defects: en route to cancer and drug resistance. Chromosome Research, 2021, 29, 131-144.	1.0	21
538	Aneuploidy as a promoter and suppressor of malignant growth. Nature Reviews Cancer, 2021, 21, 89-103.	12.8	99
539	Antagonizing the spindle assembly checkpoint silencing enhances paclitaxel and Navitoclax-mediated apoptosis with distinct mechanistic. Scientific Reports, 2021, 11, 4139.	1.6	12
541	FUCCI-Red: a single-color cell cycle indicator for fluorescence lifetime imaging. Cellular and Molecular Life Sciences, 2021, 78, 3467-3476.	2.4	11
542	The impact of phenotypic heterogeneity of tumour cells on treatment and relapse dynamics. PLoS Computational Biology, 2021, 17, e1008702.	1.5	11
543	Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors. Cell Death and Disease, 2021, 12, 268.	2.7	2
544	Multinucleation associated DNA damage blocks proliferation in p53-compromised cells. Communications Biology, 2021, 4, 451.	2.0	13
545	Automated classification of mitotic catastrophe by use of the centromere fragmentation morphology. Biochemistry and Cell Biology, 2021, 99, 261-271.	0.9	2
546	Isolation of a natural product with anti-mitotic activity from a toxic Canadian prairie plant. Heliyon, 2021, 7, e07131.	1.4	5

#	Article	IF	Citations
547	FOXM1 repression increases mitotic death upon antimitotic chemotherapy through BMF upregulation. Cell Death and Disease, 2021, 12, 542.	2.7	10
548	Combination Treatment of OSI-906 with Aurora B Inhibitor Reduces Cell Viability via Cyclin B1 Degradation-Induced Mitotic Slippage. International Journal of Molecular Sciences, 2021, 22, 5706.	1.8	4
550	A PKD-MFF signaling axis couples mitochondrial fission to mitotic progression. Cell Reports, 2021, 35, 109129.	2.9	15
551	Modulation of the anticancer activities of paclitaxel by Cremophor micelles. International Journal of Pharmaceutics, 2021, 603, 120699.	2.6	3
552	Second-Generation Antimitotics in Cancer Clinical Trials. Pharmaceutics, 2021, 13, 1011.	2.0	26
553	Epithelial proliferation and cell cycle dysregulation in kidney injury and disease. Kidney International, 2021, 100, 67-78.	2.6	20
554	Chromosome alignmentâ€maintaining phosphoprotein CHAMP1 plays a role in cell survival through regulating Mclâ€1 expression. Cancer Science, 2021, 112, 3711-3721.	1.7	6
555	Evaluation of combination protocols of the chemotherapeutic agent FX-9 with azacitidine, dichloroacetic acid, doxorubicin or carboplatin on prostate carcinoma cell lines. PLoS ONE, 2021, 16, e0256468.	1.1	0
556	Epigenetic instability may alter cell state transitions and anticancer drug resistance. PLoS Computational Biology, 2021, 17, e1009307.	1.5	6
557	Future prospects for mitosis-targeted antitumor therapies. Biochemical Pharmacology, 2021, 190, 114655.	2.0	24
559	Identification of novel microtubule inhibitors effective in fission yeast and human cells and their effects on breast cancer cell lines. Open Biology, 2021, 11, 210161.	1.5	2
560	Back to the new beginning: Mitotic exit in space and time. Seminars in Cell and Developmental Biology, 2021, 117, 140-148.	2.3	12
561	Cell cycle control in cancer. Nature Reviews Molecular Cell Biology, 2022, 23, 74-88.	16.1	499
562	Spindle assembly checkpoint activation and silencing at kinetochores. Seminars in Cell and Developmental Biology, 2021, 117, 86-98.	2.3	125
563	Analyze impact of tumor-associated kinetics on antibody delivery in solid tumors with a physiologically based pharmacokinetics/pharmacodynamics model. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 168, 110-121.	2.0	2
564	The tyrosine kinase vâ€Src modifies cytotoxicities of anticancer drugs targeting cell division. Journal of Cellular and Molecular Medicine, 2021, 25, 1677-1687.	1.6	5
565	Stiffening of DU145 prostate cancer cells driven by actin filaments â€“ microtubule crosstalk conferring resistance to microtubule-targeting drugs. Nanoscale, 2021, 13, 6212-6226.	2.8	21
566	Current and Next Generation Antimitotic Therapies in Cancer. , 2012, , 5-21.		1

#	Article	IF	Citations
567	Spindle Assembly Checkpoint: Its Control and Aberration. , 2016, , 429-447.		1
568	Effect of Chemotherapy on the Tumor Microenvironment and Anti-tumor Immunity. , 2013, , 1-28.		3
569	Histone Deacetylase Inhibitors Disrupt the Mitotic Spindle Assembly Checkpoint By Targeting Histone and Nonhistone Proteins. Advances in Cancer Research, 2012, 116, 1-37.	1.9	18
570	Microtubule-targeting agents and their impact on cancer treatment. European Journal of Cell Biology, 2020, 99, 151075.	1.6	132
576	Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis. Journal of Clinical Investigation, 2019, 129, 1329-1344.	3.9	105
577	Taxane resistance in prostate cancer is mediated by decreased drug-target engagement. Journal of Clinical Investigation, 2020, 130, 3287-3298.	3.9	31
578	Emerging approaches to target mitochondrial apoptosis in cancer cells. F1000Research, 2019, 8, 1793.	0.8	16
579	A Screen for Kinetochore-Microtubule Interaction Inhibitors Identifies Novel Antitubulin Compounds. PLoS ONE, 2010, 5, e11603.	1.1	16
580	Intravital FRET Imaging of Tumor Cell Viability and Mitosis during Chemotherapy. PLoS ONE, 2013, 8, e64029.	1.1	52
581	The 3' Untranslated Region of the Cyclin B mRNA Is Not Sufficient to Enhance the Synthesis of Cyclin B during a Mitotic Block in Human Cells. PLoS ONE, 2013, 8, e74379.	1.1	6
582	Trichostatin A Targets the Mitochondrial Respiratory Chain, Increasing Mitochondrial Reactive Oxygen Species Production to Trigger Apoptosis in Human Breast Cancer Cells. PLoS ONE, 2014, 9, e91610.	1.1	36
583	AG490 and PF431396 Sensitive Tyrosine Kinase Control the Population Heterogeneity of Basal STAT1 Activity in Ube1l Deficient Cells. PLoS ONE, 2016, 11, e0159453.	1.1	4
584	Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma. Oncotarget, 2016, 7, 86594-86607.	0.8	19
585	Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanes. Oncotarget, 2017, 8, 9189-9199.	0.8	24
586	The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models. Oncotarget, 2017, 8, 6730-6741.	0.8	34
587	Mitotic cell death induction by targeting the mitotic spindle with tubulin-inhibitory indole derivative molecules. Oncotarget, 2017, 8, 19738-19759.	0.8	19
588	Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo. Oncotarget, 2017, 8, 21153-21166.	0.8	15
589	Evidence of drug-response heterogeneity rapidly generated from a single cancer cell. Oncotarget, 2017, 8, 41113-41124.	0.8	10

#	Article	IF	Citations
590	Prolonged mitotic arrest induced by Wee1 inhibition sensitizes breast cancer cells to paclitaxel. Oncotarget, 2017, 8, 73705-73722.	0.8	44
591	The Aurora-A inhibitor MLN8237 affects multiple mitotic processes and induces dose-dependent mitotic abnormalities and aneuploidy. Oncotarget, 2014, 5, 6229-6242.	0.8	37
592	Microtubins: a novel class of small synthetic microtubule targeting drugs that inhibit cancer cell proliferation. Oncotarget, 2017, 8, 104007-104021.	0.8	7
593	Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of Polo-like kinase 1 and microtubule dynamics. Oncotarget, 2018, 9, 25842-25859.	0.8	24
594	Tumour treating fields in a combinational therapeutic approach. Oncotarget, 2018, 9, 36631-36644.	0.8	26
595	Cenp-E inhibitor GSK923295: Novel synthetic route and use as a tool to generate aneuploidy. Oncotarget, 2015, 6, 20921-20932.	0.8	42
596	Mitotic entry: Non-genetic heterogeneity exposes the requirement for Plk1. Oncotarget, 2015, 6, 36472-36488.	0.8	11
597	Mcl-1 dynamics influence mitotic slippage and death in mitosis. Oncotarget, 2016, 7, 5176-5192.	0.8	59
598	Cell fate determination in cisplatin resistance and chemosensitization. Oncotarget, 2016, 7, 23383-23394.	0.8	12
599	BCL-W is a regulator of microtubule inhibitor-induced mitotic cell death. Oncotarget, 2016, 7, 38718-38730.	0.8	20
600	Tubulins as Therapeutic Targets in Cancer: from Bench to Bedside. Current Pharmaceutical Design, 2012, 18, 2778-2792.	0.9	90
601	Multidrug Resistance Through the Spectacle of P-Glycoprotein. Current Cancer Drug Targets, 2009, 9, 281-297.	0.8	107
602	Aurora A and B Kinases - Targets of Novel Anticancer Drugs. Recent Patents on Anti-Cancer Drug Discovery, 2010, 5, 219-241.	0.8	12
603	Subtype specific biomarkers associated with chemoresistance in epithelial ovarian cancer. Indian Journal of Pathology and Microbiology, 2020, 63, 64.	0.1	5
604	Genomic Instability in Cancer II: 4N-Skewed (90°) Reductive Division via Fragile Sites to Fitness Increase for Solid and Hematological Cancer Beginnings. Journal of Cancer Therapy, 2019, 10, 537-564.	0.1	4
605	Cloning and Functional Characterization of Ptpcd2 as a Novel Cell Cycle Related Protein Tyrosine Phosphatase that Regulates Mitotic Exit. Asian Pacific Journal of Cancer Prevention, 2013, 14, 3669-3676.	0.5	1
606	Mitotic progression, arrest, exit or death relies on centromere structural integrity, rather than de novo transcription. ELife, 2018, 7, .	2.8	18
607	Spatiotemporal control of mitotic exit during anaphase by an aurora B-Cdk1 crosstalk. ELife, 2019, 8, .	2.8	39

#	Article	IF	Citations
608	ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells. PeerJ, 2013, 1, e144.	0.9	44
609	Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models. Journal of Experimental and Clinical Cancer Research, 2021, 40, 323.	3.5	12
610	The Cyclin Cln1 Controls Polyploid Titan Cell Formation following a Stress-Induced G ₂ Arrest in Cryptococcus. MBio, 2021, 12, e0250921.	1.8	19
611	Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castrationâ€resistant prostate cancer. Prostate, 2021, 82, 182.	1.2	4
612	Influence of a B16/F10 melanoma variant on the Ð'cl-2 levels in mitochondria in various organs of female mice. Bulletin of Siberian Medicine, 2021, 20, 46-53.	0.1	1
614	Mitotic Checkpoint and Chromosome Instability in Cancer. , 2010, , 59-77.		0
616	New Insights into Tubulin Binders. , 2011, , 259-278.		1
618	G2/M Arrest Sensitises Erythroid Leukemia Cells to TRAIL-induced Apoptosis. Journal of Leukemia (Los) Tj ETQq1 1 0.784314 rgBT /Ov	0.1	0
619	Cancers in Children Ages 8 to 12 Are Injury-Related. Journal of Cancer Therapy, 2015, 06, 177-181.	0.1	3
620	Cancer Prevention? Fundamental Genomic Alterations Are Present in Preneoplasia, Including Function of High Frequency Selected Mutations (HFSMs). Journal of Cancer Therapy, 2016, 07, 416-426.	0.1	2
622	Cytotoxic Effect of Bitter Melon (Momordica charantia L.) Ethanol Extract and Its Fractions on Pancreatic Cancer Cells in vitro. Exploratory Research and Hypothesis in Medicine, 2017, 2, 1-11.	0.1	3
632	Mechanism of mitotic catastrophe and its role in anticancer therapy. Postepy Higieny I Medycyny Doswiadczalnej, 2020, 74, 84-93.	0.1	0
635	Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer. EBioMedicine, 2021, 73, 103681.	2.7	6
638	Antibody-drug conjugates: an evolving approach for melanoma treatment. Melanoma Research, 2021, 31, 1-17.	0.6	4
642	Targeting mitotic exit in solid tumors. American Journal of Cancer Research, 2021, 11, 3698-3710.	1.4	0
643	Microtubule Targeting Agents in Disease: Classic Drugs, Novel Roles. Cancers, 2021, 13, 5650.	1.7	54
644	BP-M345, a New Diarylpentanoid with Promising Antimitotic Activity. Molecules, 2021, 26, 7139.	1.7	8
645	Chromatin bridges, not micronuclei, activate cGAS after drug-induced mitotic errors in human cells. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	48

#	Article	IF	Citations
646	TH588 and Low-Dose Nocodazole Impair Chromosome Congression by Suppressing Microtubule Turnover within the Mitotic Spindle. Cancers, 2021, 13, 5995.	1.7	7
648	TORC1 inactivation promotes APC/C-dependent mitotic slippage in yeast and human cells. IScience, 2022, 25, 103675.	1.9	3
649	Integrated microfluidic single-cell immunoblotting chip enables high-throughput isolation, enrichment and direct protein analysis of circulating tumor cells. Microsystems and Nanoengineering, 2022, 8, 13.	3.4	23
650	Anticancer evaluation of the selected tetrahydropyrimidines: 3D-QSAR, cytotoxic activities, mechanism of action, DNA, and BSA interactions. Journal of Molecular Structure, 2022, 1257, 132621.	1.8	7
651	Role of Senescence in Tumorigenesis and Anticancer Therapy. Journal of Oncology, 2022, 2022, 1-23.	0.6	3
652	Kinesin spindle protein inhibitors in cancer: from high throughput screening to novel therapeutic strategies. Future Science OA, 2022, 8, FSO778.	0.9	18
653	Mitotic and DNA Damage Response Proteins: Maintaining the Genome Stability and Working for the Common Good. Frontiers in Cell and Developmental Biology, 2021, 9, 700162.	1.8	5
654	The BH3-only protein NOXA serves as an independent predictor of breast cancer patient survival and defines susceptibility to microtubule targeting agents. Cell Death and Disease, 2021, 12, 1151.	2.7	11
661	Apoptotic priming is defined by the dynamic exchange of Bcl-2 proteins between mitochondria and cytosol. Cell Death and Differentiation, 2022, 29, 2262-2274.	5.0	10
662	Precise control of microtubule disassembly in living cells. EMBO Journal, 2022, 41, .	3.5	9
663	Navitoclax Enhances the Therapeutic Effects of PLK1 Targeting on Lung Cancer Cells in 2D and 3D Culture Systems. Pharmaceutics, 2022, 14, 1209.	2.0	3
664	Single-cell characterization of step-wise acquisition of carboplatin resistance in ovarian cancer. Npj Systems Biology and Applications, 2022, 8, .	1.4	2
665	The Role of the APC/C and Its Coactivators Cdh1 and Cdc20 in Cancer Development and Therapy. Frontiers in Genetics, 0, 13, .	1.1	10
667	Mitotic Catastrophe. , 2022, , .		0
668	Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action. Frontiers in Oncology, 0, 12, .	1.3	31
669	CDC20-Mediated hnRNPU Ubiquitination Regulates Chromatin Condensation and Anti-Cancer Drug Response. Cancers, 2022, 14, 3732.	1.7	5
671	Combined TRIP13 and Aurora Kinase Inhibition Induces Apoptosis in Human Papillomavirusâ€“Driven Cancers. Clinical Cancer Research, 2022, 28, 4479-4493.	3.2	4
672	Toxicity of Orthodontic Brackets Examined by Single Cell Tracking. Toxics, 2022, 10, 460.	1.6	1

#	Article	IF	Citations
673	Micronuclei from misaligned chromosomes that satisfy the spindle assembly checkpoint in cancer cells. Current Biology, 2022, 32, 4240-4254.e5.	1.8	13
674	Benzimidazole and its derivatives as cancer therapeutics: The potential role from traditional to precision medicine. Acta Pharmaceutica Sinica B, 2023, 13, 478-497.	5.7	28
675	Bcl-xL activity influences outcome of the mitotic arrest. Frontiers in Pharmacology, 0, 13, .	1.6	3
676	Comparison of Different Clinical Chemotherapeutical Agentsâ€™ Toxicity and Cell Response on Mesenchymal Stem Cells and Cancer Cells. Cells, 2022, 11, 2942.	1.8	0
677	Inhibition of Mps1 kinase enhances taxanes efficacy in castration resistant prostate cancer. Cell Death and Disease, 2022, 13, .	2.7	3
678	ER-851, a Novel Selective Inhibitor of AXL, Overcomes Resistance to Antimitotic Drugs. Molecular Cancer Therapeutics, 2023, 22, 12-24.	1.9	3
679	Drug resistance dependent on allostery: A P-loop rigor Eg5 mutant exhibits resistance to allosteric inhibition by STLC. Frontiers in Oncology, 0, 12, .	1.3	1
680	MARCH5 regulates mitotic apoptosis through MCL1-dependent and independent mechanisms. Cell Death and Differentiation, 2023, 30, 753-765.	5.0	3
681	Multiple-low-dose therapy: effective killing of high-grade serous ovarian cancer cells with ATR and CHK1 inhibitors. NAR Cancer, 2022, 4, .	1.6	3
682	The SCF-FBXW7 E3 ubiquitin ligase triggers degradation of Histone 3 Lysine 4 methyltransferase complex component WDR5 to prevent mitotic slippage. Journal of Biological Chemistry, 2022, , 102703.	1.6	4
684	Apoptosis as a Barrier against CIN and Aneuploidy. Cancers, 2023, 15, 30.	1.7	1
685	BCL-xL inhibition potentiates cancer therapies by redirecting the outcome of p53 activation from senescence to apoptosis. Cell Reports, 2022, 41, 111826.	2.9	7
686	Phytochemicals as Chemo-Preventive Agents and Signaling Molecule Modulators: Current Role in Cancer Therapeutics and Inflammation. International Journal of Molecular Sciences, 2022, 23, 15765.	1.8	12
687	Animal models of chemotherapyâ€induced peripheral neuropathy for hematological malignancies: A review. , 2023, 9, 72-89.		1
688	Cancer cell cycle heterogeneity as a critical determinant of therapeutic resistance. Genes and Diseases, 2024, 11, 189-204.	1.5	10
689	Misaligned Chromosomes are a Major Source of Chromosomal Instability in Breast Cancer. Cancer Research Communications, 2023, 3, 54-65.	0.7	8
691	Whole-Genome Duplication and Genome Instability in Cancer Cells: Double the Trouble. International Journal of Molecular Sciences, 2023, 24, 3733.	1.8	3
692	Vitamin D3 Promotes Structural and Functional Recovery After Vincristine-Induced Peripheral Neuropathy in Rats: An Experimental Study. Cureus, 2023, , .	0.2	0

#	Article	IF	Citations
694	Triap1 upregulation promotes escape from mitotic-slippage-induced G1 arrest. Cell Reports, 2023, 42, 112215.	2.9	0
695	Substances of Natural Origin in Medicine: Plants vs. Cancer. Cells, 2023, 12, 986.	1.8	14
696	Imaging Flow Cytometry of Multi-Nuclearity. Methods in Molecular Biology, 2023, , 87-101.	0.4	1
699	Anticancer drugs targeting tubulin and microtubules. , 2023, , 445-491.		0
708	Assessment of cell cycle progression and mitotic slippage by videomicroscopy. Methods in Cell Biology, 2024, , 43-58.	0.5	0
716	Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nature Reviews Immunology, 0, , .	10.6	2